[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 169
1. Amati M, Tomasetti M, Scartozzi M, Mariotti L, Ciuccarelli M, Valentino M, Governa M, Santarelli L: [Biomarkers for prevention and early diagnosis of malignant pleural mesothelioma]. G Ital Med Lav Ergon; 2007 Jul-Sep;29(3 Suppl):335-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biomarkers for prevention and early diagnosis of malignant pleural mesothelioma].
  • Improved detection methods for diagnosis of asymptomatic malignant pleural mesothelioma (MPM) are essential for an early and reliable detection and treatment of this disease.
  • 94 asbestos-exposed subjects, 22 patients with MM, and 54 healthy subjects were recruited for evaluation of the significance of 8-hydroxy-2'-deoxy-guanosine (80HdG) in white blood cells and plasma concentrations of soluble mesothelin-related peptides (SMRPs), angiogenic factors (PDGFbeta, HGF, bFGF, VEGFbeta), and matrix proteases (MMP2, MMP9, TIMP1, TIMP2) for potential early detection of MM.
  • The area under ROC curves (AUC) indicates that 80HdG levels can discriminate asbestos-exposed subjects from controls but not from MPM patients.
  • Significant AUC values were found for SMRP discriminating asbestos-exposed subjects from MPM patients but not from controls.
  • VEGFbeta can significantly differentiate asbestos-exposed subjects from control and cancer groups.
  • The combination of blood biomarkers and radiographic findings could be used to stratify the risk of mesothelioma in asbestos-exposed populations.
  • [MeSH-major] Biomarkers, Tumor / blood. Mesothelioma / diagnosis. Mesothelioma / prevention & control. Pleural Neoplasms / prevention & control


2. Larson TC, Antao VC, Bove FJ: Vermiculite worker mortality: estimated effects of occupational exposure to Libby amphibole. J Occup Environ Med; 2010 May;52(5):555-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The Cox models for mesothelioma, asbestosis, lung cancer, and non-malignant respiratory disease were significant with rate ratios that increased monotonically with CFE.
  • CONCLUSIONS: By using a within-cohort comparison, the results demonstrate a clear exposure-response relationship between CFE and mortality from asbestos-related causes.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20431408.001).
  • [ISSN] 1536-5948
  • [Journal-full-title] Journal of occupational and environmental medicine
  • [ISO-abbreviation] J. Occup. Environ. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aluminum Silicates; 0 / Asbestos, Amphibole; 1318-00-9 / vermiculite
  •  go-up   go-down


3. Pass HI, Carbone M: Current status of screening for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg; 2009;21(2):97-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of screening for malignant pleural mesothelioma.
  • Malignant mesothelioma is characterized by its association with asbestos, its long latency period, and the propensity for the diagnosis to be obtained in the later stages of the disease.
  • Because the high-risk cohorts for mesothelioma are fairly well defined by the association with asbestos, and the exposure is usually in the workplace, it is hypothesized that early detection of the disease could (1) find patients at an earlier, more treatable stage and (2) result in prolonged survival over the present median 12 months from the start of therapy.
  • Many studies have used standard chest X-ray to characterize changes associated with asbestos-exposed individuals, but the insensitivity of X-ray in screening patients with mesothelioma has never supported the wide-scale adaptation of such an effort.
  • Most recently, serum biomarkers with the potential to discriminate asbestos-exposed, non-cancer-bearing individuals from those with mesothelioma have been investigated both at single institutions and with multi-institutional-blinded trials.
  • These markers, including soluble mesothelin-related protein, osteopontin, and megakaryocyte potentiating factor, may, in the future, be incorporated into a screening algorithm for high-risk asbestos-exposed individuals to help monitor these cohorts in a noninvasive fashion and guide the use of computerized tomography.
  • [MeSH-major] Biomarkers, Tumor / blood. Mass Screening / methods. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Asbestos / adverse effects. GPI-Linked Proteins. Humans. Membrane Glycoproteins / blood. Occupational Exposure. Osteopontin / blood. Patient Selection. Predictive Value of Tests. Risk Assessment. Risk Factors

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19822280.001).
  • [ISSN] 1043-0679
  • [Journal-full-title] Seminars in thoracic and cardiovascular surgery
  • [ISO-abbreviation] Semin. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / SPP1 protein, human; 0 / mesothelin; 106441-73-0 / Osteopontin; 1332-21-4 / Asbestos
  • [Number-of-references] 70
  •  go-up   go-down


Advertisement
4. Azim HA Jr, Gaafar R, Abdel Salam I, El-Guindy S, Elattar I, Ashmawy A, Khorshid O: Soluble mesothelin-related protein in malignant pleural mesothelioma. J Egypt Natl Canc Inst; 2008 Sep;20(3):224-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble mesothelin-related protein in malignant pleural mesothelioma.
  • BACKGROUND AND PURPOSE: Building-up evidence suggests that soluble mesothelinrelated protein (SMRP) carries a diagnostic and a prognostic value in malignant pleural mesothelioma (MPM).
  • The mean SMRP concentrations were also higher in males, elderly patients, asbestos-exposed patients, epithelioid subtypes and patients with high platelet and leucocytic counts.
  • KEY WORDS: Malignant pleural mesothelioma (MPM) - Soluble mesothelin related protein (SMRP)- Sensitivity - Specificity - Asbestos.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20424652.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


5. Wilczyńska U, Szymczak W, Szeszenia-Dabrowska N: Mortality from malignant neoplasms among workers of an asbestos processing plant in Poland: results of prolonged observation. Int J Occup Med Environ Health; 2005;18(4):313-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality from malignant neoplasms among workers of an asbestos processing plant in Poland: results of prolonged observation.
  • OBJECTIVES: The study on mortality from cancer among workers of an asbestos plant manufacturing asbestos yarn, cloth, cords, packings, stuffing, brake linings and asbestos-rubber sheets was launched in the 1980s.
  • The present paper discusses the results of further tracing of asbestos workers of the same plant.
  • MATERIALS AND METHODS: The study cohort covered 4497 workers employed at the asbestos plant in 1945-1980.
  • Mortality from malignant neoplasms in total (281 deaths among men, SMR = 118, 95%CI: 105-133 and 135 deaths among women, SMR = 159, 95%CI: 133-188) as well as that from lung cancer (102 deaths among men, SMR = 126, 95%CI: 103-153 and 18 deaths among women, SMR = 259, 95%CI: 153-409) were significantly higher than in the general population.
  • Unlike earlier stages of analysis, the present study revealed an increased risk of pleural mesothelioma (2 deaths among men, SMR = 510, 95%CI: 62-1842 and 3 deaths among women, SMR = 2033, 95%CI: 419-5941).
  • Mortality analysis among workers with asbestosis and in those without diagnosed asbestosis, did not reveal direct association between the risk of asbestos-induced lung cancer and previously diagnosed asbestosis.
  • CONCLUSIONS: The prolonged cohort tracing showed an increased risk of asbestos-related cancers.
  • [MeSH-major] Asbestos / adverse effects. Mesothelioma / mortality

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16617847.001).
  • [ISSN] 1232-1087
  • [Journal-full-title] International journal of occupational medicine and environmental health
  • [ISO-abbreviation] Int J Occup Med Environ Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 1332-21-4 / Asbestos
  •  go-up   go-down


6. Nymark P, Lindholm PM, Korpela MV, Lahti L, Ruosaari S, Kaski S, Hollmén J, Anttila S, Kinnula VL, Knuutila S: Gene expression profiles in asbestos-exposed epithelial and mesothelial lung cell lines. BMC Genomics; 2007;8:62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiles in asbestos-exposed epithelial and mesothelial lung cell lines.
  • BACKGROUND: Asbestos has been shown to cause chromosomal damage and DNA aberrations.
  • Exposure to asbestos causes many lung diseases e.g. asbestosis, malignant mesothelioma, and lung cancer, but the disease-related processes are still largely unknown.
  • We exposed the human cell lines A549, Beas-2B and Met5A to crocidolite asbestos and determined time-dependent gene expression profiles by using Affymetrix arrays.
  • RESULTS: We recognized a large number of previously known as well as new potential asbestos-associated genes and biological processes, and identified chromosomal regions enriched with genes potentially contributing to common responses to asbestos in these cell lines.
  • CONCLUSION: This study identifies several interesting targets for further investigation in relation to asbestos-associated diseases.
  • [MeSH-major] Asbestos, Crocidolite / toxicity. Epithelium / drug effects. Gene Expression Profiling. Lung / drug effects

  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Cell Mol Biol. 1999 Nov;21(5):637-46 [10536123.001]
  • [Cites] Br J Ind Med. 1991 Feb;48(2):103-5 [1998603.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2000;19(1-2):13-9 [10905503.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Sep;29(1):1-8 [10918387.001]
  • [Cites] Mutat Res. 2000 Oct 10;470(1):77-84 [10986477.001]
  • [Cites] Carcinogenesis. 2000 Nov;21(11):2005-10 [11062161.001]
  • [Cites] Am J Respir Cell Mol Biol. 2001 Apr;24(4):427-35 [11306436.001]
  • [Cites] Int J Cancer. 2001 May 20;95(3):198-204 [11307155.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2001;20(2):97-108 [11394717.001]
  • [Cites] Cancer Genet Cytogenet. 2001 May;127(1):80-2 [11408072.001]
  • [Cites] Mutat Res. 2002 Feb 15;514(1-2):7-17 [11815240.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):1991-2000 [12057904.001]
  • [Cites] J Pathol. 2002 Jul;197(3):363-71 [12115883.001]
  • [Cites] Oncogene. 2002 Oct 21;21(48):7284-8 [12379872.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Int J Biochem Cell Biol. 2003 Aug;35(8):1198-209 [12757757.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Sep;29(3 Suppl):S51-8 [14503555.001]
  • [Cites] Nucleic Acids Res. 1992 Aug 11;20(15):3821-30 [1508666.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3299-303 [8386370.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 1;91(5):1672-6 [8127864.001]
  • [Cites] Hum Exp Toxicol. 1994 Jan;13(1):3-9 [8198827.001]
  • [Cites] Free Radic Biol Med. 1996;21(4):527-32 [8886804.001]
  • [Cites] Br J Cancer. 1997;75(4):523-7 [9052404.001]
  • [Cites] Carcinogenesis. 1997 Apr;18(4):825-32 [9111221.001]
  • [Cites] Am J Pathol. 1998 Feb;152(2):333-40 [9466557.001]
  • [Cites] Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1666-80 [9603153.001]
  • [Cites] Toxicol Appl Pharmacol. 1998 Jul;151(1):88-97 [9705890.001]
  • [Cites] Am J Respir Cell Mol Biol. 1998 Sep;19(3):445-52 [9730872.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8702-7 [15574780.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):17-25 [15447976.001]
  • [Cites] Am J Respir Cell Mol Biol. 2005 May;32(5):395-403 [15695738.001]
  • [Cites] Am J Pathol. 2005 Jun;166(6):1827-40 [15920167.001]
  • [Cites] Biochim Biophys Acta. 2005 May 30;1740(2):215-21 [15949689.001]
  • [Cites] Bioinformatics. 2005 Jun;21 Suppl 1:i159-68 [15961453.001]
  • [Cites] Am J Pathol. 2005 Nov;167(5):1243-56 [16251409.001]
  • [Cites] Virchows Arch. 2006 Feb;448(2):135-41 [16170537.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):2970-9 [16540645.001]
  • [Cites] Genome Res. 2006 May;16(5):567-75 [16651663.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5737-43 [16740712.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10397-402 [16798876.001]
  • [Cites] Antioxid Redox Signal. 2006 Jul-Aug;8(7-8):1249-52 [16910772.001]
  • [Cites] Oncogene. 2007 Jul 12;26(32):4730-7 [17297452.001]
  • [Cites] Oncogene. 2004 Aug 26;23(39):6672-6 [15221014.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jan;36(1):9-16 [14592528.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):849-59 [14871960.001]
  • [Cites] Bioinformatics. 2004 Feb 12;20(3):307-15 [14960456.001]
  • [Cites] BMC Bioinformatics. 2004 Mar 29;5:34 [15050037.001]
  • [Cites] Nat Rev Immunol. 2004 Aug;4(8):641-8 [15286730.001]
  • [Cites] Res Commun Chem Pathol Pharmacol. 1988 Aug;61(2):201-11 [2847261.001]
  • [Cites] Br J Cancer. 1989 Oct;60(4):618-26 [2803935.001]
  • [Cites] Br J Cancer. 1999 Dec;81(7):1111-5 [10584869.001]
  • (PMID = 17331233.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 12001-28-4 / Asbestos, Crocidolite
  • [Other-IDs] NLM/ PMC1821332
  •  go-up   go-down


7. Weber DG, Johnen G, Taeger D, Weber A, Gross IM, Pesch B, Kraus T, Brüning T, Gube M: Assessment of Confounding Factors Affecting the Tumor Markers SMRP, CA125, and CYFRA21-1 in Serum. Biomark Insights; 2010 Jan 28;5:1-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this analysis was to evaluate if serum levels of potential tumor markers for the diagnosis of malignant mesothelioma and lung cancer are affected by confounding factors in a surveillance cohort of workers formerly exposed to asbestos.
  • SMRP, CA125, and CYFRA21-1 concentrations were determined in about 1,700 serum samples from 627 workers formerly exposed to asbestos.
  • Levels differed by study centers and were higher after 40 years of asbestos exposure.
  • Tumor marker concentrations are influenced by subject-related factors, sample handling, and storage.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chem. 2009 Jul;55(7):1431-3 [19406915.001]
  • [Cites] Cancer Detect Prev. 2000;24(1):86-90 [10757127.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Oct 15;178(8):832-7 [18583574.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2480-7 [18768519.001]
  • [Cites] Lung Cancer. 2008 Aug;61(2):235-43 [18281122.001]
  • [Cites] PLoS One. 2007;2(12):e1281 [18060075.001]
  • [Cites] Ann Thorac Surg. 2008 Jan;85(1):265-72; discussion 272 [18154821.001]
  • [Cites] Cancer Biomark. 2007;3(6):287-92 [18048966.001]
  • [Cites] Scand J Clin Lab Invest. 2007;67(7):741-7 [17852813.001]
  • [Cites] Chest. 2007 Oct;132(4):1239-46 [17646232.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5076-81 [17785560.001]
  • [Cites] Curr Opin Pulm Med. 2007 Jul;13(4):339-443 [17534183.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2928-35 [17504993.001]
  • [Cites] Clin Chem Lab Med. 2007;45(5):634-8 [17484626.001]
  • [Cites] Clin Chem. 2007 Apr;53(4):666-72 [17289801.001]
  • [Cites] Chest. 2004 Dec;126(6):1757-63 [15596670.001]
  • [Cites] Am Heart J. 1999 Jun;137(6):1044-9 [10347329.001]
  • [Cites] Br J Dis Chest. 1983 Oct;77(4):321-43 [6357260.001]
  • [Cites] Clin Chem Lab Med. 2004;42(7):758-64 [15327011.001]
  • [Cites] Lancet. 2003 Nov 15;362(9396):1612-6 [14630441.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Chest. 2001 Apr;119(4):1138-42 [11296181.001]
  • [Cites] Clin Biochem. 2000 Jul;33(5):405-10 [11018693.001]
  • [Cites] Mutat Res. 2000 Jul 10;468(2):195-202 [10882896.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):646-50 [19190155.001]
  • (PMID = 20130785.001).
  • [ISSN] 1177-2719
  • [Journal-full-title] Biomarker insights
  • [ISO-abbreviation] Biomark Insights
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2814766
  • [Keywords] NOTNLM ; CA125 / CYFRA21-1 / SMRP / lung cancer / mesothelin / mesothelioma / screening
  •  go-up   go-down


8. Yasuda M, Hanagiri T, Shigematsu Y, Onitsuka T, Kuroda K, Baba T, Mizukami M, Ichiki Y, Uramoto H, Takenoyama M, Yasumoto K: Identification of a tumour associated antigen in lung cancer patients with asbestos exposure. Anticancer Res; 2010 Jul;30(7):2631-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a tumour associated antigen in lung cancer patients with asbestos exposure.
  • BACKGROUND: This study analysed the humoral immune response in asbestos exposed lung cancer patients to identify new surrogate markers of the carcinogenic risk in populations exposed to asbestos.
  • METHODS AND RESULTS: A serological analysis identified five distinct antigens reactive with IgG derived from a lung cancer patient with high asbestos exposure.
  • In one of the isolated antigens, quantitative RT-PCR indicated that annexin A2 (AnxA2) was overexpressed in lung cancer tissues and normal lung from patients with high asbestos exposure.
  • Antibody against AnxA2 was detected in 9/15 (60%) of lung cancer patients with high asbestos exposure; however, in only 1/12 (8%) of lung cancer patients with low asbestos exposure.
  • AnxA2 was also overexpressed in malignant mesothelioma cells, and the antibody was also positive in 8/15 (53%) of patients with malignant mesothelioma.
  • CONCLUSION: The antibody titer against AnxA2 may be a potentially useful new diagnostic surrogate marker for asbestos-related lung cancer and malignant mesothelioma.
  • [MeSH-major] Antigens, Neoplasm / immunology. Asbestos / poisoning. Lung Neoplasms / etiology. Lung Neoplasms / immunology
  • [MeSH-minor] Aged. Aged, 80 and over. Annexin A2 / biosynthesis. Annexin A2 / immunology. Antibodies, Neoplasm / immunology. Enzyme-Linked Immunosorbent Assay. Humans. Immunity, Humoral / immunology. Immunoglobulin G / immunology. Interleukin-6 / blood. Interleukin-6 / immunology. Male. Mesothelioma / etiology. Mesothelioma / immunology. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ASBESTOS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20682992.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ANXA2 protein, human; 0 / Annexin A2; 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Immunoglobulin G; 0 / Interleukin-6; 1332-21-4 / Asbestos
  •  go-up   go-down


9. Chee J, Singh J, Naran A, Misso NL, Thompson PJ, Bhoola KD: Novel expression of kallikreins, kallikrein-related peptidases and kinin receptors in human pleural mesothelioma. Biol Chem; 2007 Nov;388(11):1235-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel expression of kallikreins, kallikrein-related peptidases and kinin receptors in human pleural mesothelioma.
  • Malignant mesothelioma is an aggressive cancer of the pleura that is causally related to exposure to asbestos fibres.
  • The kallikrein serine proteases [tissue (hK1) and plasma (hKB1) kallikreins, and kallikrein-related peptidases (KRP/hK2-15)] and the mitogenic kinin peptides may have a role in tumourigenesis.
  • The expression of hK1, hKB1, KRP/hK2, 5, 6, 7, 8 and 9, and kinin B(1) and B(2) receptors was assessed in archived selected normal tissue and mesothelioma tumour sections by immunoperoxidase and immunofluorescence labelling. hK1, hKB1 and kinin B(1) and B(2) receptors were expressed in malignant cells of the epithelioid and sarcomatoid components of biphasic mesothelioma tumour cells.
  • KRP/hK2, 6, 8 and 9 were also expressed in the cytoplasm and nuclei of mesothelioma cells, whereas KRP/hK5 and hK7 showed predominantly cytoplasmic localisation.
  • This is a first report, but further studies are required to determine whether these proteins have a functional role in the pathogenesis of mesothelioma and/or may be potential biomarkers for pleural mesothelioma.
  • [MeSH-major] Kallikreins / metabolism. Kinins / metabolism. Mesothelioma / metabolism. Peptide Hydrolases / metabolism. Pleural Neoplasms / metabolism. Receptors, Cell Surface / metabolism

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17976017.001).
  • [ISSN] 1431-6730
  • [Journal-full-title] Biological chemistry
  • [ISO-abbreviation] Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Kinins; 0 / Receptors, Cell Surface; EC 3.4.- / Peptide Hydrolases; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


10. Roggli VL: The role of analytical SEM in the determination of causation in malignant mesothelioma. Ultrastruct Pathol; 2006 Jan-Feb;30(1):31-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of analytical SEM in the determination of causation in malignant mesothelioma.
  • The causative relationship between asbestos exposure and mesothelioma is firmly established.
  • The author has had the opportunity to study the lung asbestos content of 396 cases of mesothelioma, including 28 peritoneal cases, by means of analytical scanning electron microscopy.
  • Elevated tissue asbestos content was identified in 87% of pleural and 75% of peritoneal cases.
  • Peritoneal cases that are asbestos related have on average a higher lung fiber burden than pleural cases.
  • Mesotheliomas in women have elevated tissue asbestos content in about 60% of cases, and many of these had a history of exposure as a household contact of an asbestos worker.
  • [MeSH-major] Mesothelioma / ultrastructure. Microscopy, Electron, Scanning / methods. Peritoneal Neoplasms / ultrastructure. Pleural Neoplasms / ultrastructure
  • [MeSH-minor] Asbestos, Amosite / adverse effects. Asbestos, Amosite / analysis. Asbestos, Amosite / classification. Electron Probe Microanalysis. Female. Humans. Lung / ultrastructure. Peritoneum / ultrastructure. Pleura / ultrastructure

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. AMOSITE ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16517468.001).
  • [ISSN] 1521-0758
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 12172-73-5 / Asbestos, Amosite
  •  go-up   go-down


11. Miura Y, Nishimura Y, Maeda M, Murakami S, Hayashi H, Fukuoka K, Kishimoto T, Nakano T, Otsuki T: Immunological alterations found in mesothelioma patients and supporting experimental evidence. Environ Health Prev Med; 2008 Mar;13(2):55-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunological alterations found in mesothelioma patients and supporting experimental evidence.
  • It is common knowledge that exposure to asbestos causes asbestos-related diseases, such as asbestosis, lung cancer and malignant mesothelioma, not only in people who have had long-term contact with asbestos in their work environment but also in residents living near factories that handle asbestos.
  • We have focused on the immunological effects of both asbestos and silica on the human immune system.
  • In this brief review, we introduce immunological alterations found in patients with malignant mesothelioma and describe the experimental background in which these were found.
  • Analyzing the immunological effects of asbestos may improve our understanding of the biological effects of asbestos.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2004 Aug;45 Suppl 1:S7-S15 [15261426.001]
  • [Cites] J Am Med Womens Assoc. 1998 Winter;53(1):21-4, 40 [9458621.001]
  • [Cites] Br J Rheumatol. 1997 Jun;36(6):622-9 [9236670.001]
  • [Cites] Virchows Arch. 2001 May;438(5):492-7 [11407478.001]
  • [Cites] Apoptosis. 2006 Oct;11(10):1825-35 [16850164.001]
  • [Cites] Int J Tuberc Lung Dis. 2007 Apr;11(4):356-69 [17394680.001]
  • [Cites] Thorax. 1958 Sep;13(3):181-4 [13580971.001]
  • [Cites] Growth Factors. 1994;11(1):29-44 [7833058.001]
  • [Cites] Scand J Immunol. 2005 May;61(5):442-8 [15882436.001]
  • [Cites] Clin Exp Metastasis. 1998 Aug;16(6):529-39 [9872600.001]
  • [Cites] Clin Exp Immunol. 1994 Nov;98(2):319-22 [7955539.001]
  • [Cites] Curr Opin Immunol. 1998 Aug;10(4):465-70 [9722924.001]
  • [Cites] Curr Rheumatol Rep. 2004 Oct;6(5):367-74 [15355749.001]
  • [Cites] Annu Rev Immunol. 1999;17:435-66 [10358765.001]
  • [Cites] Oncology (Williston Park). 1993 Jul;7(7):17-24; discussion 24, 28, 30 [8347458.001]
  • [Cites] Int Immunopharmacol. 2002 Feb;2(2-3):303-13 [11811933.001]
  • [Cites] Cancer Res. 1987 Dec 1;47(23):6180-4 [3479241.001]
  • [Cites] Ann N Y Acad Sci. 1991 Dec 31;643:465-72 [1809160.001]
  • [Cites] Int J Immunopathol Pharmacol. 2006 Oct-Dec;19(4):795-805 [17166401.001]
  • [Cites] Ind Health. 2001 Apr;39(2):84-93 [11341562.001]
  • [Cites] Ann Allergy Asthma Immunol. 2001 Sep;87(3):181-8 [11570613.001]
  • [Cites] Proc R Soc Med. 1959 Dec;52:1111-3 [13807528.001]
  • [Cites] Clin Cancer Res. 2004 Sep 1;10(17):5907-18 [15355924.001]
  • [Cites] Ann Plast Surg. 1992 May;28(5):491-9; discussion 499-501 [1622027.001]
  • [Cites] Toxicology. 2002 Dec 27;181-182:65-70 [12505286.001]
  • [Cites] Int J Oncol. 1998 Jun;12(6):1355-9 [9592199.001]
  • [Cites] J Pathol. 1996 Feb;178(2):151-60 [8683381.001]
  • [Cites] Am Fam Physician. 2007 Mar 1;75(5):683-8 [17375514.001]
  • [Cites] Exp Cell Res. 1992 May;200(1):83-8 [1314190.001]
  • [Cites] Thorax. 1953 Mar;8(1):29-37 [13038735.001]
  • (PMID = 19568881.001).
  • [ISSN] 1342-078X
  • [Journal-full-title] Environmental health and preventive medicine
  • [ISO-abbreviation] Environ Health Prev Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2698266
  •  go-up   go-down


12. Ramos-Nino ME, Testa JR, Altomare DA, Pass HI, Carbone M, Bocchetta M, Mossman BT: Cellular and molecular parameters of mesothelioma. J Cell Biochem; 2006 Jul 1;98(4):723-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular and molecular parameters of mesothelioma.
  • Malignant mesotheliomas (MM) are neoplasms arising from mesothelial cells that line the body cavities, most commonly the pleural and peritoneal cavities.
  • Although traditionally recognized as associated with occupational asbestos exposures, MMs can appear in individuals with no documented exposures to asbestos fibers, and emerging data suggest that genetic susceptibility and simian virus 40 (SV40) infections also facilitate the development of MMs.
  • Both asbestos exposure and transfection of human mesothelial cells with SV40 large and small antigens (Tag, tag) cause genetic modifications and cell signaling events, most notably the induction of cell survival pathways and activation of receptors, and other proteins that favor the growth and establishment of MMs as well as their resistance to chemotherapy.
  • More importantly, serum proteomics has revealed two new candidates (osteopontin and serum mesothelin-related protein or SMRP) potentially useful in screening individuals for MMs.

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • [Cites] Am J Respir Cell Mol Biol. 2003 Aug;29(2):198-205 [12626342.001]
  • [Cites] Exp Lung Res. 2001 Oct-Nov;27(7):605-16 [11597120.001]
  • [Cites] FASEB J. 2001 Nov;15(13):2326-36 [11689458.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 Feb;26(2):167-70 [11804865.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 Feb;26(2):189-93 [11804869.001]
  • [Cites] Oncogene. 2002 Feb 14;21(8):1141-9 [11850833.001]
  • [Cites] Tumori. 2002 Jan-Feb;88(1):1-9 [12004841.001]
  • [Cites] Toxicol Lett. 2002 Feb 28;127(1-3):251-7 [12052665.001]
  • [Cites] Cancer Res. 1994 Mar 15;54(6):1561-5 [7511044.001]
  • [Cites] Bull Cancer. 1993 Oct;80(10):833-44 [7515731.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5547-51 [7923195.001]
  • [Cites] Arch Biochem Biophys. 1994 Nov 1;314(2):384-91 [7979379.001]
  • [Cites] Cancer Res. 1995 Feb 1;55(3):530-6 [7530596.001]
  • [Cites] Science. 1995 Feb 10;267(5199):776-7 [7710525.001]
  • [Cites] Cancer Res. 1995 Mar 15;55(6):1227-31 [7882313.001]
  • [Cites] Am J Physiol. 1995 Mar;268(3 Pt 1):L471-80 [7900829.001]
  • [Cites] Cancer Res. 1995 Aug 15;55(16):3634-9 [7627973.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8458-62 [7667311.001]
  • [Cites] Int J Exp Pathol. 1995 Aug;76(4):287-98 [7547443.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10854-8 [7479897.001]
  • [Cites] Br J Cancer. 1996 Feb;73(3):377-81 [8562345.001]
  • [Cites] Am J Respir Cell Mol Biol. 1996 Jul;15(1):141-7 [8679218.001]
  • [Cites] Cancer Res. 1996 Sep 1;56(17):4044-8 [8752177.001]
  • [Cites] Cancer Invest. 1996;14(5):466-80 [8816862.001]
  • [Cites] Am J Respir Crit Care Med. 1996 Oct;154(4 Pt 1):1124-40 [8887617.001]
  • [Cites] J Clin Invest. 1996 Nov 1;98(9):2050-9 [8903324.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5334-8 [8968079.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5256-62 [15958571.001]
  • [Cites] Adv Cancer Res. 2005;94:29-86 [16095999.001]
  • [Cites] Oncogene. 2005 Sep 8;24(40):6080-9 [15897870.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8090-5 [16166281.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1564-73 [16221779.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1591-603 [16221782.001]
  • [Cites] Med Lav. 2005 Jul-Aug;96(4):360-9 [16457433.001]
  • [Cites] Cancer J Sci Am. 1995 Sep-Oct;1(3):196-203 [9166476.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1857-62 [12060628.001]
  • [Cites] Eur Respir J. 1999 Sep;14(3):706-16 [10543297.001]
  • [Cites] J Cell Biochem. 1999 Dec;76(2):181-8 [10618635.001]
  • [Cites] J Cell Biochem. 1999 Dec;76(2):189-93 [10618636.001]
  • [Cites] Carcinogenesis. 2000 May;21(5):1023-9 [10783328.001]
  • [Cites] Eur Respir J. 2000 Jun;15(6):1069-78 [10885426.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3696-700 [10919635.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10214-9 [10954737.001]
  • [Cites] FEBS Lett. 2000 Sep 1;480(2-3):95-100 [11034307.001]
  • [Cites] Carcinogenesis. 2000 Dec;21(12):2275-80 [11133818.001]
  • [Cites] Int J Oncol. 2001 Feb;18(2):425-33 [11172613.001]
  • [Cites] Ind Health. 2002 Apr;40(2):175-81 [12064559.001]
  • [Cites] Med Electron Microsc. 2002 Mar;35(1):16-23 [12111403.001]
  • [Cites] Carcinogenesis. 2002 Jul;23(7):1127-30 [12117769.001]
  • [Cites] Toxicol Sci. 2002 Aug;68(2):331-8 [12151629.001]
  • [Cites] Mol Cell Biochem. 2002 May-Jun;234-235(1-2):111-8 [12162423.001]
  • [Cites] Ann Occup Hyg. 2002 Jul;46(5):447-53 [12176759.001]
  • [Cites] Hum Pathol. 2002 Jul;33(7):748-55 [12196927.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):4963-7 [12208747.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6065-9 [12414630.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2002 Dec;283(6):L1161-78 [12424143.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Feb;28(2):241-8 [12540492.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):598-605 [12697852.001]
  • [Cites] Free Radic Biol Med. 2003 May 1;34(9):1117-29 [12706492.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3539-45 [12839939.001]
  • [Cites] Carcinogenesis. 1997 Apr;18(4):825-32 [9111221.001]
  • [Cites] Arch Biochem Biophys. 1997 Apr 15;340(2):369-75 [9143343.001]
  • [Cites] Am J Pathol. 1997 Aug;151(2):389-401 [9250152.001]
  • [Cites] Nat Med. 1997 Aug;3(8):908-12 [9256284.001]
  • [Cites] Nat Med. 1997 Aug;3(8):913-6 [9256285.001]
  • [Cites] Am J Respir Cell Mol Biol. 1997 Sep;17(3):265-71 [9308911.001]
  • [Cites] Ann Occup Hyg. 1997 Dec;41(6):699-705 [9375528.001]
  • [Cites] Environ Health Perspect. 1997 Sep;105 Suppl 5:1061-7 [9400701.001]
  • [Cites] Environ Health Perspect. 1997 Sep;105 Suppl 5:1329-36 [9400747.001]
  • [Cites] Am J Pathol. 1998 Feb;152(2):333-40 [9466557.001]
  • [Cites] Cancer Causes Control. 1997 May;8(3):491-503 [9498906.001]
  • [Cites] Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1666-80 [9603153.001]
  • [Cites] Dev Biol Stand. 1998;94:321-8 [9776253.001]
  • [Cites] Eur Respir J. 1998 Oct;12(4):972-81 [9817178.001]
  • [Cites] Int J Oncol. 1999 Jan;14(1):181-8 [9863027.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):25-31 [10389973.001]
  • [Cites] J Cell Physiol. 1999 Aug;180(2):150-7 [10395284.001]
  • [Cites] Oncology (Williston Park). 1999 Jul;13(7):919-26; discussion 926, 931-2 [10442339.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Mar;24(3):238-42 [10451704.001]
  • [Cites] J Clin Pathol. 1999 Apr;52(4):291-3 [10474522.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7780-6 [15520183.001]
  • [Cites] Lung Cancer. 2005 Apr;48(1):19-29 [15777968.001]
  • [Cites] Mol Cancer Ther. 2005 May;4(5):835-42 [15897248.001]
  • [Cites] Am J Pathol. 2005 Jun;166(6):1827-40 [15920167.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S109-11 [15950789.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S99-S103 [15950812.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):3080-97 [12912960.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2003 Nov;285(5):L1018-25 [12909582.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jan;36(1):9-16 [14592528.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):849-59 [14871960.001]
  • [Cites] Biochimie. 2004 Jan;86(1):13-9 [14987796.001]
  • [Cites] Biochim Biophys Acta. 2004 Apr 5;1688(3):237-44 [15062874.001]
  • [Cites] Occup Environ Med. 2004 May;61(5):438-41 [15090665.001]
  • [Cites] Clin Lung Cancer. 2004 Apr;5 Suppl 2:S46-50 [15117424.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jul 1;152(1):42-51 [15193440.001]
  • [Cites] Cancer Res. 1983 Oct;43(10):4906-12 [6883341.001]
  • [Cites] Arch Biochem Biophys. 1984 Jan;228(1):373-6 [6320737.001]
  • [Cites] Br J Ind Med. 1984 Aug;41(3):389-95 [6331496.001]
  • [Cites] Am Rev Respir Dis. 1984 Dec;130(6):1042-5 [6095707.001]
  • [Cites] Cancer Res. 1987 Mar 15;47(6):1681-6 [3028612.001]
  • [Cites] Chem Biol Interact. 1987;62(1):89-97 [3034439.001]
  • [Cites] Chest. 1988 Mar;93(3):621-8 [2830081.001]
  • [Cites] In Vitro Cell Dev Biol. 1988 Nov;24(11):1077-84 [2461356.001]
  • [Cites] N Engl J Med. 1989 Jun 29;320(26):1721-30 [2659987.001]
  • [Cites] Science. 1990 Jan 19;247(4940):294-301 [2153315.001]
  • [Cites] Mol Aspects Med. 1990;11(5):325-49 [2203959.001]
  • [Cites] Cell. 1991 Apr 5;65(1):13-24 [1707342.001]
  • [Cites] J Cell Biol. 1992 Jan;116(2):521-31 [1730766.001]
  • [Cites] Free Radic Biol Med. 1992;12(4):293-315 [1577332.001]
  • [Cites] J Cell Biol. 1992 Aug;118(4):971-7 [1380003.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3299-303 [8386370.001]
  • [Cites] Cancer Res. 1993 Jun 15;53(12):2858-64 [7684950.001]
  • [Cites] Lancet. 2001 Feb 10;357(9254):444-5 [11273069.001]
  • [Cites] Semin Cancer Biol. 2001 Feb;11(1):5-13 [11243894.001]
  • [Cites] Semin Cancer Biol. 2001 Feb;11(1):63-71 [11243900.001]
  • [Cites] Int J Cancer. 2001 Feb 15;91(4):492-6 [11251971.001]
  • [Cites] Differentiation. 2000 Dec;66(4-5):181-8 [11269944.001]
  • [Cites] Bull Cancer. 2001 Mar;88(3):305-13 [11313208.001]
  • [Cites] Am J Respir Cell Mol Biol. 2001 Jun;24(6):694-702 [11415934.001]
  • [Cites] Biochem J. 2001 Aug 1;357(Pt 3):843-50 [11463356.001]
  • [Cites] Histopathology. 2001 Aug;39(2):179-86 [11493335.001]
  • [Cites] Br J Cancer. 2001 Aug 17;85(4):600-7 [11506502.001]
  • [Cites] Am J Epidemiol. 2001 Sep 15;154(6):538-43 [11549559.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12032-7 [11572935.001]
  • (PMID = 16795078.001).
  • [ISSN] 0730-2312
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K01 CA104159; United States / NCI NIH HHS / CA / P01 CA114047; United States / NCI NIH HHS / CA / R01 CA106567-01A1; United States / NCI NIH HHS / CA / R01 CA045745; United States / NCI NIH HHS / CA / R01 CA045745-12; United States / NCI NIH HHS / CA / K01 CA104159-01; United States / NCI NIH HHS / CA / CA106567-01A1; United States / NCI NIH HHS / CA / R01 CA106567; United States / NCI NIH HHS / CA / K01CA104159-01; United States / NCI NIH HHS / CA / R01CA10656; United States / NCI NIH HHS / CA / R01CA082657-01; United States / NCI NIH HHS / CA / CA045745-12; United States / NCI NIH HHS / CA / CA45745; United States / NCI NIH HHS / CA / CA104159-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  • [Number-of-references] 129
  • [Other-IDs] NLM/ NIHMS150985; NLM/ PMC2766267
  •  go-up   go-down


13. Scripcariu V, Dajbog E, Lefter L, Ferariu D, Pricop A, Grigoraş M, Dragomir C: [Malignant peritoneal mesothelioma]. Chirurgia (Bucur); 2006 Nov-Dec;101(6):641-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant peritoneal mesothelioma].
  • Mesothelioma is a neoplasm originating from the mesothelial surface lining cells of the serous human cavities.
  • Asbestos has been widely used in industry.
  • A causal relationship between asbestos exposure and pleural, peritoneal and pericardial malign mesothelioma was suggested, the risk of cancer being correlated to cumulate exposure.
  • Studies from National Cancer Institute, USA, show that the malignant mesothelioma is a rare and aggressive asbestos related malignancy.
  • This paper presents the case of a 59 year old patient with malignant peritoneal mesothelioma who worked almost 40 years as an electrician, exposed to asbestos fibers.
  • [MeSH-major] Asbestos / adverse effects. Mesothelioma / etiology. Occupational Diseases / etiology. Peritoneal Neoplasms / etiology


14. Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Bruno R, Landi D, Gemignani F, Landi S: Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein. Occup Environ Med; 2010 Apr;67(4):233-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein.
  • BACKGROUND: Serum mesothelin, also known as soluble mesothelin-related protein (SMRP), reportedly shows increased levels in epithelial-type malignant pleural mesothelioma, but sometimes also arrives at high values in healthy asbestos-exposed subjects.
  • METHODS: The 3'UTR of the mesothelin gene was genotyped in 59 healthy asbestos-exposed subjects, selected on the basis of their SMRP levels.
  • RESULTS: High levels of SMRP in healthy asbestos-exposed subjects were significantly associated with polymorphism rs1057147 (G<A).
  • [MeSH-minor] Asbestos / toxicity. Biomarkers, Tumor / blood. GPI-Linked Proteins. Humans. Male. Mesothelioma / blood. MicroRNAs / genetics. Middle Aged. Occupational Diseases / blood. Occupational Exposure / adverse effects. Pleural Neoplasms / blood. Prognosis. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Asbestos.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19858537.001).
  • [ISSN] 1470-7926
  • [Journal-full-title] Occupational and environmental medicine
  • [ISO-abbreviation] Occup Environ Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / MicroRNAs; 0 / mesothelin; 1332-21-4 / Asbestos
  •  go-up   go-down


15. Comar M, Rizzardi C, de Zotti R, Melato M, Bovenzi M, Butel JS, Campello C: SV40 multiple tissue infection and asbestos exposure in a hyperendemic area for malignant mesothelioma. Cancer Res; 2007 Sep 15;67(18):8456-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SV40 multiple tissue infection and asbestos exposure in a hyperendemic area for malignant mesothelioma.
  • To assess the presence of SV40 in malignant mesothelioma tissue, 19 formalin-fixed paraffin-embedded pleural cancer samples of patients from a hyperendemic area of northeastern Italy were analyzed retrospectively.
  • A total of 48 other tissues from the malignant mesothelioma subjects were investigated.
  • Exposure to asbestos was evaluated through a careful review of the occupational history of patients, supplemented by histology and isolation of asbestos bodies.
  • Three of 19 (15.8%) malignant mesothelioma tissues harbored SV40 genomic signals.
  • Two patients with SV40-positive malignant mesothelioma had viral sequences in another tissue.
  • SV40 viral loads were higher in malignant mesothelioma than in normal cells (P = 0.045).
  • This survey shows that SV40 sustains infections in multiple tissues in malignant mesothelioma patients from a geographic area affected with asbestos-related mesothelioma.
  • [MeSH-major] Asbestos / adverse effects. Cocarcinogenesis. Mesothelioma / etiology. Pleural Neoplasms / etiology. Polyomavirus Infections / complications. Simian virus 40 / genetics. Tumor Virus Infections / complications

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875683.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA104818
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 1332-21-4 / Asbestos
  •  go-up   go-down


16. Lotti M, Bergamo L, Murer B: Occupational toxicology of asbestos-related malignancies. Clin Toxicol (Phila); 2010 Jul;48(6):485-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occupational toxicology of asbestos-related malignancies.
  • INTRODUCTION: Asbestos is banned in most Western countries but related malignancies are still of clinical concern because of their long latencies.
  • This review identifies and addresses some controversial occupational and clinical aspects of asbestos-related malignancies.
  • In addition, fibers and asbestos bodies are counted in lung tissue, broncho-alveolar lavage, and sputum, but different techniques and interlaboratory variability hamper the interpretation of reported measurements.
  • Several biomarkers have also been considered to screen individuals at risk for lung cancer and mesothelioma but reliable signatures are still missing.
  • However, the unresolved question is whether the presence of fibrosis is a requirement for the attribution of lung cancer to asbestos.
  • The etiology of lung cancer is difficult to define in cases of low-level asbestos exposure and concurrent smoking habits.
  • MESOTHELIOMA: The diagnosis of malignant mesothelioma may also be difficult, because of procedures in sampling, fixation, and processing, and uses of immunohistochemical probes.
  • Quantitative analysis of asbestos body burden is better performed in digested lung tissues by counting asbestos bodies by light microscopy and/or uncoated fibers by transmission electron microscopy.
  • The benefits of screenings for asbestos-related malignancies are equivocal.
  • The attribution of lung cancer to asbestos exposure is difficult in a clinical setting because of the need to assess asbestos body burden and the fact that virtually all these patients are also tobacco smokers or former smokers.
  • Given the premise that asbestosis is necessary to causally link lung cancer to asbestos, it follows that the assessment of both lung fibrosis and asbestos body burden is necessary.
  • [MeSH-major] Asbestos / toxicity. Lung Neoplasms / chemically induced. Mesothelioma / chemically induced. Occupational Exposure / adverse effects

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20849338.001).
  • [ISSN] 1556-9519
  • [Journal-full-title] Clinical toxicology (Philadelphia, Pa.)
  • [ISO-abbreviation] Clin Toxicol (Phila)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 1332-21-4 / Asbestos
  •  go-up   go-down


17. Cvitanović S, Ivancević Z, Capkun V, Tenzera-Taslak G: [Incidence of malignant pleural mesothelioma in Split-Dalmatia County]. Arh Hig Rada Toksikol; 2009 Nov;60 Suppl:31-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incidence of malignant pleural mesothelioma in Split-Dalmatia County].
  • Between 2001 and 2005, 1150 patients with respiratory symptoms were admitted to our Pneumology Clinic whose workplace or residence could involve exposure to asbestos One hundred and twenty (10.4%) patients were confirmed a disease of the lung and/or pleura which could have been asbestos-related.
  • A follow-up of these patients showed that 52 of 120 (43.3%) developed malignant pleural mesothelioma (MPM), but it was also found in 12 of 1030 (1.1%) patients without an asbestos-related disease.
  • Fifty-two (81.2%) were professionally or residentially exposed to asbestos.
  • This distribution of MPM may be related to the strong shipbuilding industry and other asbestos-related industries in this part of the country.
  • [MeSH-major] Asbestos / adverse effects. Mesothelioma / epidemiology. Pleural Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20853776.001).
  • [ISSN] 0004-1254
  • [Journal-full-title] Arhiv za higijenu rada i toksikologiju
  • [ISO-abbreviation] Arh Hig Rada Toksikol
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


18. Witherby SM, Butnor KJ, Grunberg SM: Malignant mesothelioma following thoracic radiotherapy for lung cancer. Lung Cancer; 2007 Sep;57(3):410-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma following thoracic radiotherapy for lung cancer.
  • Although some of these malignancies may be related to common environmental exposures, a significant number are considered to be therapy-related.
  • Pleural malignant mesothelioma is a neoplasm that may be related to asbestos exposure or radiation exposure.
  • Previous reports of pleural mesothelioma as a second malignancy have tended to follow radiotherapy for extra-thoracic malignancies such as Hodgkin's disease, breast cancer and Wilms' tumor.
  • We report the case of a 66-year-old woman with no prior asbestos exposure who developed pleural mesothelioma 17 years after pneumonectomy and adjuvant radiation therapy for non-small cell lung cancer.
  • Secondary malignancies such as mesothelioma should be considered in patients who develop unexplained symptoms even long after treatment of a primary tumor.
  • [MeSH-major] Lung Neoplasms / radiotherapy. Mesothelioma / diagnosis. Neoplasms, Radiation-Induced / diagnosis. Neoplasms, Second Primary / diagnosis. Pleural Neoplasms / diagnosis


19. Phillips JI, Murray J: Malignant mesothelioma in a patient with anthophyllite asbestos fibres in the lungs. Ann Occup Hyg; 2010 Jun;54(4):412-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma in a patient with anthophyllite asbestos fibres in the lungs.
  • The amphibole asbestos, anthophyllite, is associated with asbestos-related disease in humans, along with mesothelioma in animal models.
  • In humans, however, there are only three cases of histologically proven malignant mesothelioma of the pleura associated with anthophyllite that have been documented in the English-language literature.
  • Using scanning electron microscopy, his lung fibre burden was calculated to be 358,000 fibres and 31,000 asbestos bodies per gram of dry weight of lung tissue.
  • No other types of asbestos were detected in the lung.
  • He worked in the plastic manufacturing industry and was exposed to talc and asbestos blankets that were used to insulate machinery.
  • [MeSH-major] Asbestos, Amphibole / toxicity. Mesothelioma / diagnosis. Occupational Diseases / diagnosis. Pleural Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • Hazardous Substances Data Bank. TALC .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20427324.001).
  • [ISSN] 1475-3162
  • [Journal-full-title] The Annals of occupational hygiene
  • [ISO-abbreviation] Ann Occup Hyg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Asbestos, Amphibole; 0 / Mineral Fibers; 0 / Plastics; 14807-96-6 / Talc; 61029-21-8 / anthophyllite
  •  go-up   go-down


20. Partemi S, De Giorgio F: Medico-legal aspects of mesothelioma. Ann Ital Chir; 2007 Sep-Oct;78(5):401-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medico-legal aspects of mesothelioma.
  • The Authors, reviewing the Literature on asbestos-related Malignant Mesothelioma (MM), found that because of its very peculiar characteristics, the causal link between professional asbestos exposure and the development of this tumour is very difficult to define in respect to: diagnosis, causal link and individuation of possible culpable conducts.
  • In fact it is sufficient, that asbestos-related lesions are ascertained in individuals who are or were exposed at any time of their professional life to the risk of inhaling asbestos fibres.
  • [MeSH-major] Mesothelioma. Occupational Diseases. Workers' Compensation / legislation & jurisprudence

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18338548.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 15
  •  go-up   go-down


21. Candura SM, Binarelli A, Ragno G, Scafa F: Two cases of asbestosis and one case of rounded atelectasis due to non-occupational asbestos exposure. Monaldi Arch Chest Dis; 2008 Mar;69(1):35-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of asbestosis and one case of rounded atelectasis due to non-occupational asbestos exposure.
  • Asbestos is a well-known cause of several neoplastic (malignant mesothelioma, lung cancer) and non-neoplastic (asbestosis, pleuropathies) occupational diseases.
  • Lower-level exposure in the general environment may induce pleural plaques and thickenings, and is associated with an increased mesothelioma risk.
  • We present two patients (a 68-year-old man and a 72-year-old woman) who developed asbestosis (in association with pleural plaques and calcifications), and a 78-year-old man who developed rounded atelectasis (with pleural plaques and benign effusion), after living for several decades in the proximity of large Italian asbestos-cement plant.
  • None of them had been exposed to asbestos occupationally.
  • Besides living in a contaminated area, the woman used to clean the work clothes of her brother, who was employed in the local asbestos factory.
  • The three cases indicate that non-neoplastic, long-latency asbestos-related diseases which are usually observed as a consequence of occupational exposures, may rarely develop in subjects living in contaminated geographical sites and buildings.

  • Genetic Alliance. consumer health - Asbestosis.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Collapsed Lung.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507198.001).
  • [ISSN] 1122-0643
  • [Journal-full-title] Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace
  • [ISO-abbreviation] Monaldi Arch Chest Dis
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


22. Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, Horick N, Skates SJ, Robinson BW: Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest; 2007 Oct;132(4):1239-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
  • BACKGROUND: Malignant mesothelioma is an aggressive, uniformly fatal tumor.
  • The purpose of this study was to study the mesothelin biomarker in a large patient cohort and to determine if another biomarker, CA125, improves on the sensitivity of mesothelin in the diagnosis of mesothelioma.
  • METHODS: Serum levels of mesothelin and CA125 were determined by commercially available assays in 117 samples obtained at diagnosis from patients with pleural malignant mesothelioma, 33 healthy, asbestos-exposed individuals, 53 patients with asbestos-related lung or pleural disease, and 30 patients presenting with benign pleural effusions.
  • RESULTS: CA125 had a cross-validated sensitivity of 27% for mesothelioma patients at a specificity of 95% relative to asbestos-exposed individuals, or 50% relative to individuals with benign pleural effusions.
  • Mesothelin had a cross-validated sensitivity of 52% for mesothelioma patients, at a sensitivity of 95% relative to individuals with benign lung or pleural disease.
  • CA125 and mesothelin levels were discordant in > 50% of mesothelioma patients.
  • Combining the data from the two biomarkers using a logistic regression model did not improve sensitivity for detecting mesothelioma above that of the mesothelin marker alone.
  • CONCLUSION: Combining mesothelin and CA125 data does not improve the sensitivity of mesothelioma diagnosis over mesothelin alone.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Membrane Glycoproteins / blood. Mesothelioma / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646232.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


23. Pala C, Paliogiannis P, Serventi F, Trignano E, Trignano M: Multimodality approach to malignant pleural mesothelioma. A case report. Ann Ital Chir; 2010 Jan-Feb;81(1):37-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality approach to malignant pleural mesothelioma. A case report.
  • INTRODUCTION: We report a case of diffuse malignant pleural mesothelioma (DMPM) in a 68-years-old male patient who was admitted for right sited pleural effusion.
  • Anamnesis revealed professional asbestos exposure and the patient presented dyspnea, dry cough, right sited chest pain, low fever and loss of weight.
  • Histological examination of the specimens extracted revealed the presence of epithelial malignant pleural mesothelioma with sarcomatoid areas.
  • The disease free period was of about one year and the patient died after 31 months from diagnosis for septic complications related to chronic effusion.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593749.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


24. Riehemann K, Schmitt O, Ehlers EM: The effects of thermochemotherapy using cyclophosphamide plus hyperthermia on the malignant pleural mesothelioma in vivo. Ann Anat; 2005 Jul;187(3):215-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of thermochemotherapy using cyclophosphamide plus hyperthermia on the malignant pleural mesothelioma in vivo.
  • The human malignant pleural mesothelioma is related to the use of asbestos in the majority of cases.
  • Though the use of asbestos has been prohibited since the 1990s, the incidence of pleural mesothelioma is still increasing because of a latency period of at least 20 years.
  • This study investigated the benefit of single therapy with cyclophosphamide or hyperthermia or the combination of both on cells of a human pleural mesothelioma cell line, xenotransplanted subcutaneously in the paw of mice.
  • This study shows promising results in the treatment of malignant pleural mesothelioma.
  • [MeSH-major] Cyclophosphamide / therapeutic use. Hyperthermia, Induced. Mesothelioma / therapy. Pleural Neoplasms / therapy

  • Genetic Alliance. consumer health - Malignant hyperthermia.
  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16130821.001).
  • [ISSN] 0940-9602
  • [Journal-full-title] Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft
  • [ISO-abbreviation] Ann. Anat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


25. Neri M, Taioli E, Filiberti R, Paolo Ivaldi G, Aldo Canessa P, Verna A, Marroni P, Puntoni R, Hirvonen A, Garte S: Metabolic genotypes as modulators of asbestos-related pleural malignant mesothelioma risk: a comparison of Finnish and Italian populations. Int J Hyg Environ Health; 2006 Jul;209(4):393-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic genotypes as modulators of asbestos-related pleural malignant mesothelioma risk: a comparison of Finnish and Italian populations.
  • The role of CYP1A1, GSTM1, GSTT1, EPHX1, and NAT2 genotypes in susceptibility to malignant mesothelioma (MM) was compared in two case-control studies, previously conducted in two countries where different types of asbestos fibers have been used [Hirvonen et al., 1995.
  • Inherited GSTM1 and NAT2 defects as concurrent risk modifiers in asbestos-related human malignant mesothelioma.
  • Glutathione S-Transferase and N-Acetyltransferase genotypes and asbestos-associated pulmonary disorders. J. Natl.
  • Pleural malignant mesothelioma, genetic susceptibility and asbestos exposure. Mutat. Res. 592, 36-44].
  • Fifty-seven asbestos-exposed MM patients and 255 controls were recruited in Italy, 48 cases and 121 controls in Finland.
  • The opposite results obtained in Finland and Italy may be ascribed to random chance, but a role may be hypothesized for the fact that different types of asbestos have been used in the two countries.
  • [MeSH-major] Asbestos / toxicity. Genetic Predisposition to Disease. Mesothelioma / genetics. Pleural Neoplasms / genetics

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16697254.001).
  • [ISSN] 1438-4639
  • [Journal-full-title] International journal of hygiene and environmental health
  • [ISO-abbreviation] Int J Hyg Environ Health
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 1332-21-4 / Asbestos; EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / NAT2 protein, human; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1; EC 3.3.2.- / Epoxide Hydrolases
  •  go-up   go-down


26. Busacca S, Germano S, De Cecco L, Rinaldi M, Comoglio F, Favero F, Murer B, Mutti L, Pierotti M, Gaudino G: MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol; 2010 Mar;42(3):312-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications.
  • Human malignant mesothelioma is an asbestos-related cancer, with poor prognosis and low median survival.
  • Here we report, for the first time, a cross-evaluation of miRNA expression in mesothelioma (MPP-89, REN) and human mesothelial cells (HMC-telomerase reverse transcriptase).
  • Microarray profiling, confirmed by real-time quantitative RT-PCR, revealed a differential expression of miRNAs between mesothelioma and mesothelial cells.
  • Several predicted genes belong to terms of Gene Ontology (GO) that are associated with the development and progression of mesothelioma.
  • This suggests that miRNAs may be key players in mesothelioma oncogenesis.
  • We further investigated miRNA expression on a panel of 24 mesothelioma specimens, representative of the three histotypes (epithelioid, biphasic, and sarcomatoid), by quantitative RT-PCR.
  • Our preliminary analysis points at miRNAs as potential diagnostic and prognostic markers of mesothelioma, and suggests novel tools for the therapy of this malignancy.
  • [MeSH-major] Gene Expression Profiling. Mesothelioma / diagnosis. Mesothelioma / genetics. MicroRNAs / genetics

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19502386.001).
  • [ISSN] 1535-4989
  • [Journal-full-title] American journal of respiratory cell and molecular biology
  • [ISO-abbreviation] Am. J. Respir. Cell Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MicroRNAs
  •  go-up   go-down


27. Yildirim H, Metintas M, Entok E, Ak G, Ak I, Dundar E, Erginel S: Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study. J Thorac Oncol; 2009 Dec;4(12):1480-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
  • In this pilot study, we investigate the role of 18F-FDG positron emission tomography/computed tomography (PET/CT) for differentiating asbestos-related benign pleural disease from malignant mesothelioma.
  • MATERIALS AND METHODS: The study population comprised 31 consecutive patients (17 malignant mesotheliomas, nine benign asbestos pleurisies, and five diffuse pleural fibrosis) with a mean age of 61 years between January 2006 and December 2008.
  • Thoracoscopy or image-guided pleural needle biopsy were systematically performed to reveal pathologic diagnosis and/or clinical follow-up for at least 3 years for presence or absence of malignant pleural effusion.
  • ROCs analyses for standardized uptake value (SUV) adjusted to body weight were calculated between benign and malignant pleural diseases.
  • RESULTS: 18F-FDG PET/CT imaging correctly detected the presence of malignancies in 15 of 17 patients with malignant mesothelioma for sensitivity, specificity, and overall accuracy of 88.2%, 92.9%, and 90.3%, respectively.
  • The mean SUV values were 6.5 +/- 3.4 for malignant mesothelioma cases and 0.8 +/- 0.6 for benign pleural diseases (p < 0.001).
  • CONCLUSION: Preliminary results of this trial provide evidence that 18F-FDG PET/CT imaging is a highly accurate and reliable noninvasive test to decide for further investigation of differentiating malignant mesothelioma from benign pleural disease.
  • [MeSH-major] Asbestos / adverse effects. Fluorodeoxyglucose F18. Mesothelioma / radionuclide imaging. Pleural Diseases / radionuclide imaging. Pleural Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19875971.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 1332-21-4 / Asbestos
  •  go-up   go-down


28. Currie AJ, van der Most RG, Broomfield SA, Prosser AC, Tovey MG, Robinson BW: Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors. J Immunol; 2008 Feb 1;180(3):1535-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated this response by injecting a range of TLR agonists into established tumors using a mouse model of malignant mesothelioma stably transduced with the hemagglutinin (HA) gene as a marker Ag (AB1-HA).
  • [MeSH-major] CD8-Positive T-Lymphocytes / immunology. Immunity, Innate. Interferon-alpha / metabolism. Interferon-beta / metabolism. Mesothelioma / immunology

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18209049.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Ligands; 0 / Nucleic Acids; 0 / RNA, Double-Stranded; 24939-03-5 / Poly I-C; 77238-31-4 / Interferon-beta
  •  go-up   go-down


29. Kothmaier H, Quehenberger F, Halbwedl I, Morbini P, Demirag F, Zeren H, Comin CE, Murer B, Cagle PT, Attanoos R, Gibbs AR, Galateau-Salle F, Popper HH: EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors. Thorax; 2008 Apr;63(4):345-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors.
  • BACKGROUND: Malignant pleural mesothelioma (MPM) is an asbestos related tumour difficult to detect early and treat effectively.
  • Asbestos causes genetic modifications and cell signalling events that favour the resistance of MPM to apoptosis and chemotherapy.
  • Antiapoptosis was upregulated in STS by signal transducer and activator of transcription 1 (STAT1)-survivin and related molecules, but not in LTS.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Mesothelioma / pathology. Neoplasm Proteins / metabolism. Pleural Neoplasms / pathology. Receptor, Epidermal Growth Factor / metabolism. Receptors, Platelet-Derived Growth Factor / metabolism


30. Harb A, King E, Lloyd H, Harb Z, Payne JG: Primary omental mesothelioma: a rare but important differential diagnosis in previous asbestos exposure. J Gastrointest Surg; 2010 Feb;14(2):423-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary omental mesothelioma: a rare but important differential diagnosis in previous asbestos exposure.
  • Primary omental mesothelioma is a malignant tumour of the mesothelial cells of the omentum, related to asbestos exposure.
  • We present a review of the related literature and report on a fatal case of primary omental mesothelioma in a 70 year old man, presenting with a painful abdominal mass.
  • [MeSH-major] Asbestosis. Mesothelioma / diagnosis. Occupational Exposure. Omentum / pathology. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Aged. Asbestos / adverse effects. Diagnosis, Differential. Fatal Outcome. Humans. Male

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1031-51 [12883236.001]
  • [Cites] Surg Today. 2004;34(9):780-3 [15338355.001]
  • [Cites] AJR Am J Roentgenol. 1984 Nov;143(5):1075-7 [6333150.001]
  • [Cites] Zentralbl Gynakol. 1983;105(9):598-601 [6880476.001]
  • (PMID = 19424765.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


31. Marinaccio A, Binazzi A, Cauzillo G, Cavone D, Zotti RD, Ferrante P, Gennaro V, Gorini G, Menegozzo M, Mensi C, Merler E, Mirabelli D, Montanaro F, Musti M, Pannelli F, Romanelli A, Scarselli A, Tumino R, Italian Mesothelioma Register (ReNaM) Working Group: Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. Eur J Cancer; 2007 Dec;43(18):2722-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register.
  • Italy was an important producer of raw asbestos until 1992 (when it was banned) and it is now experiencing severe public health consequences due to large-scale industrial use of asbestos in shipbuilding and repair, asbestos-cement production, railways, buildings, chemicals and many other industrial sectors.
  • Latency of malignant mesothelioma generally shows a large variability and the relationship with the modality of asbestos exposure is still not fully clarified.
  • We present an analysis of latency period among the case list collected by the Italian mesothelioma register (ReNaM) in the period of diagnosis 1993-2001 (2544 malignant mesothelioma (MM) cases with asbestos exposure history).
  • The role of diagnostic confidence level, the morphology of the tumour and the modalities of asbestos exposure were verified in a regression multivariate model.
  • [MeSH-major] Asbestos / toxicity. Environmental Exposure / adverse effects. Heart Neoplasms / epidemiology. Mesothelioma / epidemiology. Peritoneal Neoplasms / epidemiology. Pleural Neoplasms / epidemiology. Testicular Neoplasms / epidemiology


32. Creaney J, Robinson BW: Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein. Hematol Oncol Clin North Am; 2005 Dec;19(6):1025-40, v
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein.
  • Malignant mesothelioma (MM) is strongly associated with asbestos exposure.
  • Measurement of soluble mesothelin-related protein (SMRP) levels in the serum may prove valuable as an adjunct to current tests for the diagnosis of MM and for monitoring MM patients for the early detection of disease recurrence.
  • Although individuals with occupational and nonoccupational asbestos exposure are justifiably concerned about their risk of developing MM, consideration must be given to the complex issues surrounding screening for this disease, and a more substantial evaluation of the SMRP marker must be undertaken before deciding to promote a screening program.
  • [MeSH-major] Asbestos / adverse effects. Mesothelioma / diagnosis. Mesothelioma / etiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16325121.001).
  • [ISSN] 0889-8588
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 1332-21-4 / Asbestos
  • [Number-of-references] 62
  •  go-up   go-down


33. Thomas DD, Espey MG, Pociask DA, Ridnour LA, Donzelli S, Wink DA: Asbestos redirects nitric oxide signaling through rapid catalytic conversion to nitrite. Cancer Res; 2006 Dec 15;66(24):11600-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asbestos redirects nitric oxide signaling through rapid catalytic conversion to nitrite.
  • Asbestos exposure is strongly associated with the development of malignant mesothelioma, yet the mechanistic basis of this observation has not been resolved.
  • Carcinogenic transformation or tumor progression mediated by asbestos may be related to the generation of free radical species and perturbation of cell signaling and transcription factors.
  • We report here that exposure of human mesothelioma or lung carcinoma cells to nitric oxide (NO) in the presence of crocidolite asbestos resulted in a marked decrease in intracellular nitrosation and diminished NO-induced posttranslational modifications of tumor-associated proteins (hypoxia-inducible factor-1alpha and p53).
  • Nitrated protein adducts are a prominent feature of asbestos-induced lung injury.
  • These data highlight the ability of asbestos to induce phenotypic cellular changes through two processes: (a) by directly reducing bioactive NO levels and preventing its subsequent interaction with target molecules and (b) by increasing oxidative damage and protein modifications through NO(2) production and 3-nitrotyrosine formation.
  • [MeSH-major] Asbestos / pharmacology. Nitric Oxide / physiology. Nitrites / metabolism. Serum Albumin, Bovine / drug effects. Signal Transduction / drug effects

  • MedlinePlus Health Information. consumer health - Asbestos.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. ASBESTOS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17178853.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Nitrites; 0 / Serum Albumin, Bovine; 0 / Tumor Suppressor Protein p53; 1332-21-4 / Asbestos; 17885-08-4 / Phosphoserine; 31C4KY9ESH / Nitric Oxide
  •  go-up   go-down


34. Hillegass JM, Shukla A, MacPherson MB, Lathrop SA, Alexeeva V, Perkins TN, van der Vliet A, Vacek PM, Gunter ME, Mossman BT: Mechanisms of oxidative stress and alterations in gene expression by Libby six-mix in human mesothelial cells. Part Fibre Toxicol; 2010 Sep 11;7:26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Exposures to an amphibole fiber in Libby, Montana cause increases in malignant mesothelioma (MM), a tumor of the pleural and peritoneal cavities with a poor prognosis.
  • Affymetrix microarray/GeneSifter analysis was used to determine alterations in gene expression of a human mesothelial cell line (LP9/TERT-1) by a non-toxic concentration (15×10(6) μm2/cm2) of unprocessed Libby six-mix and negative (glass beads) and positive (crocidolite asbestos) controls.
  • A dose-related increase in SOD2 activity was observed, although total SOD activity remained unchanged.
  • Both Libby six-mix and crocidolite asbestos at 75×10(6) μm2/cm2 caused transient decreases (p < 0.05) in GSH for up to 24 h and increases in gene expression of heme oxygenase 1 (HO-1) in LP9/TERT-1 and HKNM-2 cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 2000 Jan;59(2):163-70 [10817351.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3696-700 [10919635.001]
  • [Cites] Free Radic Biol Med. 2003 May 1;34(9):1117-29 [12706492.001]
  • [Cites] Free Radic Biol Med. 2003 Jun 1;34(11):1359-68 [12757846.001]
  • [Cites] Environ Health Perspect. 2003 Nov;111(14):1753-9 [14594627.001]
  • [Cites] Occup Environ Med. 2004 Apr;61(4):363-6 [15031396.001]
  • [Cites] Mutat Res. 2004 Sep 3;553(1-2):111-24 [15288538.001]
  • [Cites] Am J Ind Med. 2004 Sep;46(3):219-25 [15307120.001]
  • [Cites] Lab Invest. 1986 Feb;54(2):204-12 [3945053.001]
  • [Cites] J Clin Invest. 1992 Apr;89(4):1257-67 [1556187.001]
  • [Cites] J Biol Chem. 1992 May 25;267(15):10625-30 [1316905.001]
  • [Cites] Am J Pathol. 1992 Aug;141(2):475-85 [1323223.001]
  • [Cites] J Lab Clin Med. 1994 Feb;123(2):183-97 [8301193.001]
  • [Cites] Am J Respir Cell Mol Biol. 1994 Mar;10(3):245-52 [8117443.001]
  • [Cites] Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):795-802 [8118652.001]
  • [Cites] Free Radic Biol Med. 1996;21(2):125-31 [8818626.001]
  • [Cites] Free Radic Biol Med. 1996;21(4):527-32 [8886804.001]
  • [Cites] Br J Haematol. 2000 Mar;108(3):574-81 [10759716.001]
  • [Cites] Br J Cancer. 2000 Mar;82(5):1022-9 [10737384.001]
  • [Cites] Mol Cell Biol. 2000 Feb;20(4):1436-47 [10648628.001]
  • [Cites] J Surg Res. 2000 Feb;88(2):130-4 [10644478.001]
  • [Cites] Am J Respir Cell Mol Biol. 1998 Apr;18(4):570-80 [9533946.001]
  • [Cites] J Toxicol Environ Health A. 2010;73(5):423-36 [20155583.001]
  • [Cites] Environ Toxicol. 2010 Feb;25(1):68-76 [19219932.001]
  • [Cites] Am J Respir Cell Mol Biol. 2009 Jul;41(1):114-23 [19097984.001]
  • [Cites] J Cancer Res Clin Oncol. 1999;125(6):327-35 [10363564.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7780-6 [15520183.001]
  • [Cites] Drug Metab Rev. 2004 Oct;36(3-4):747-62 [15554245.001]
  • [Cites] Toxicology. 2005 Jan 15;206(2):299-308 [15588921.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1591-603 [16221782.001]
  • [Cites] Am J Pathol. 2005 Nov;167(5):1243-56 [16251409.001]
  • [Cites] FASEB J. 2006 May;20(7):997-9 [16571779.001]
  • [Cites] Inhal Toxicol. 2006 Nov;18(12):925-40 [16920666.001]
  • [Cites] Inhal Toxicol. 2006 Nov;18(12):941-7 [16920667.001]
  • [Cites] Am J Pathol. 2007 Jan;170(1):140-51 [17200189.001]
  • [Cites] Am J Respir Cell Mol Biol. 2007 Mar;36(3):333-42 [17038662.001]
  • [Cites] Int J Cancer. 2007 Jun 15;120(12):2739-43 [17290392.001]
  • [Cites] Toxicol Sci. 2007 Sep;99(1):277-88 [17578862.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2007;53 Suppl:OL965-80 [17695086.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10260-7 [17974967.001]
  • [Cites] J Immunotoxicol. 2008 Apr;5(2):139-44 [18569383.001]
  • [Cites] Am J Ind Med. 2008 Nov;51(11):877-80 [18651576.001]
  • [Cites] Regul Toxicol Pharmacol. 2008 Oct;52(1 Suppl):S97-S109 [18006127.001]
  • (PMID = 20831825.001).
  • [ISSN] 1743-8977
  • [Journal-full-title] Particle and fibre toxicology
  • [ISO-abbreviation] Part Fibre Toxicol
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL085646; United States / NIEHS NIH HHS / ES / T32ES007122
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Asbestos, Amphibole; 0 / Reactive Oxygen Species; 12001-28-4 / Asbestos, Crocidolite; EC 1.14.99.3 / HMOX1 protein, human; EC 1.14.99.3 / Heme Oxygenase-1; EC 1.15.1.1 / Superoxide Dismutase; EC 1.15.1.1 / superoxide dismutase 2; GAN16C9B8O / Glutathione
  • [Other-IDs] NLM/ PMC2945990
  •  go-up   go-down


35. Lee KH, Yoon HS, Choi SJ, Kang D: Asbestos exposure and malignant mesothelioma in Korea. Asian Pac J Cancer Prev; 2009 Oct-Dec;10(4):707-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asbestos exposure and malignant mesothelioma in Korea.
  • Although importation of asbestos to Korea has decreased, there are growing concerns of its hazardous effects.
  • This paper describes the use and occupational exposure to asbestos, and the incidence and mortality of malignant mesotheliomas in Korea.
  • Asbestos raw material imports from other countries peaked between 1990 and 1995, but importation of asbestos-containing and -processed materials has steadily increased until now.
  • The average airborne asbestos concentration was lower than from other countries and steadily decreased during the study period.
  • The number of malignant mesothelioma cases in Korea was 48 in 1998, 39 in 1999, 45 in 2000, 38 in 2001, and 46 in 2002.
  • There were 334 deaths due to malignant mesothelioma and an average of 30.4 deaths per year between 1996 and 2006.
  • The number of deaths attributed to malignant mesothelioma ranged from 16 cases in 1999 to 57 cases in 2006.
  • The magnitude of asbestos-related health problems in Korea has been underestimated due to under-diagnosis, incomplete reports, and shorter duration of exposure.
  • A nationwide surveillance system for asbestos exposure and malignant mesothelioma should therefore be implemented.
  • [MeSH-major] Asbestos / adverse effects. Mesothelioma / etiology. Occupational Exposure / adverse effects. Pleural Neoplasms / etiology


36. Pinton G, Brunelli E, Murer B, Puntoni R, Puntoni M, Fennell DA, Gaudino G, Mutti L, Moro L: Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res; 2009 Jun 1;69(11):4598-604
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.
  • Malignant pleural mesothelioma is an asbestos-related neoplasm with poor prognosis, refractory to current therapies, the incidence of which is expected to increase in the next decades.
  • Female gender was identified as a positive prognostic factor among other clinical and biological prognostic markers for malignant mesothelioma, yet a role of estrogen receptors (ERs) has not been studied.
  • Our goal was to investigate ERs expression in malignant mesothelioma and to assess whether their expression correlates with prognosis.
  • Multivariate analysis of 78 malignant mesothelioma patients with pathologic stage, histologic type, therapy, sex, and age at diagnosis indicated that ERbeta expression is an independent prognostic factor of better survival.
  • Moreover, studies in vitro confirmed that treatment with 17beta-estradiol led to an ERbeta-mediated inhibition of malignant mesothelioma cell proliferation as well as p21(CIP1) and p27(KIP1) up-regulation.
  • Our data support the notion that ERbeta acting as a tumor suppressor is of high potential relevance to prediction of disease progression and to therapeutic response of malignant mesothelioma patients.
  • [MeSH-major] Estrogen Receptor beta / metabolism. Estrogen Receptor beta / physiology. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis


37. Belyanskaya LL, Marti TM, Hopkins-Donaldson S, Kurtz S, Felley-Bosco E, Stahel RA: Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer; 2007;6:66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.
  • BACKGROUND: The incidence of malignant pleural mesothelioma (MPM) is associated with exposure to asbestos, and projections suggest that the yearly number of deaths in Western Europe due to MPM will increase until 2020.
  • Inducing apoptosis by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or agonistic monoclonal antibodies which target TRAIL-receptor 1 (TRAIL-R1) or TRAIL-R2 has been thought to be a promising cancer therapy.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Apoptosis / drug effects. Cisplatin / pharmacology. Mesothelioma / drug therapy. Receptors, TNF-Related Apoptosis-Inducing Ligand / immunology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1998 Aug 28;281(5381):1305-8 [9721089.001]
  • [Cites] J Immunol. 1998 Sep 15;161(6):2833-40 [9743343.001]
  • [Cites] Curr Opin Immunol. 1998 Oct;10(5):552-8 [9794838.001]
  • [Cites] J Biol Chem. 1999 Jan 15;274(3):1541-8 [9880531.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):666-72 [10027347.001]
  • [Cites] J Biol Chem. 2005 Jan 21;280(3):2205-12 [15520016.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1430-41 [15846298.001]
  • [Cites] BMC Cancer. 2005;5:54 [15916713.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):501-10 [16098063.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7436-45 [16103097.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6881-9 [16192580.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):230-42 [16003725.001]
  • [Cites] Am J Respir Cell Mol Biol. 2005 Dec;33(6):541-8 [16123394.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):876-85 [16239906.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11265-70 [16357130.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9394-407 [16361639.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1740-50 [16452234.001]
  • [Cites] FEBS Lett. 2006 May 15;580(11):2671-6 [16647070.001]
  • [Cites] Neoplasia. 2006 Jul;8(7):551-9 [16867217.001]
  • [Cites] Cancer J. 2006 Jul-Aug;12(4):257-73 [16925970.001]
  • [Cites] Oncogene. 2006 Aug 24;25(37):5145-54 [16636678.001]
  • [Cites] J Cell Biochem. 2006 Aug 1;98(5):1284-95 [16514644.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(14):2233-40 [16884904.001]
  • [Cites] J Pathol. 2007 Mar;211(4):447-54 [17253596.001]
  • [Cites] J Surg Res. 2007 Jul;141(1):120-31 [17574045.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2805-9 [10850418.001]
  • [Cites] Cell. 2000 Jul 7;102(1):1-4 [10929706.001]
  • [Cites] J Biol Chem. 2000 Jul 28;275(30):23319-25 [10770955.001]
  • [Cites] Oncogene. 2001 Jan 18;20(3):399-403 [11313970.001]
  • [Cites] Pathol Oncol Res. 2001;7(2):95-106 [11458271.001]
  • [Cites] Am J Respir Cell Mol Biol. 2001 Jul;25(1):111-8 [11472983.001]
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3247-57 [11714700.001]
  • [Cites] Cell. 2002 Jan 25;108(2):153-64 [11832206.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):2-17 [11836664.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):277-88 [12001989.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):420-30 [12189384.001]
  • [Cites] Cell Death Differ. 2003 Mar;10(3):356-64 [12700635.001]
  • [Cites] Oncogene. 2003 May 15;22(19):2869-81 [12771938.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):3134-41 [12912965.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 30;314(1):186-91 [14715264.001]
  • [Cites] Br J Cancer. 2004 Mar 8;90(5):1022-4 [14997201.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1644-53 [15083198.001]
  • [Cites] Vitam Horm. 2004;67:365-83 [15110186.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3451-7 [15337794.001]
  • [Cites] Oncogene. 2004 Oct 14;23(47):7753-60 [15334061.001]
  • [Cites] Int J Cancer. 1992 May 8;51(2):296-301 [1373705.001]
  • [Cites] Immunity. 1995 Dec;3(6):673-82 [8777713.001]
  • (PMID = 17953743.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / TNFRSF10A protein, human; 0 / TNFRSF10B protein, human; 0 / lexatumumab; 0 / mapatumumab; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2134932
  •  go-up   go-down


38. Yang H, Rivera Z, Jube S, Nasu M, Bertino P, Goparaju C, Franzoso G, Lotze MT, Krausz T, Pass HI, Bianchi ME, Carbone M: Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A; 2010 Jul 13;107(28):12611-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation.
  • Asbestos carcinogenesis has been linked to the release of cytokines and mutagenic reactive oxygen species (ROS) from inflammatory cells.
  • Asbestos is cytotoxic to human mesothelial cells (HM), which appears counterintuitive for a carcinogen.
  • We show that asbestos-induced HM cell death is a regulated form of necrosis that links to carcinogenesis.
  • Asbestos-exposed HM activate poly(ADP-ribose) polymerase, secrete H(2)O(2), deplete ATP, and translocate high-mobility group box 1 protein (HMGB1) from the nucleus to the cytoplasm, and into the extracellular space.
  • The release of HMGB1 induces macrophages to secrete TNF-alpha, which protects HM from asbestos-induced cell death and triggers a chronic inflammatory response; both favor HM transformation.
  • In both mice and hamsters injected with asbestos, HMGB1 was specifically detected in the nuclei, cytoplasm, and extracellular space of mesothelial and inflammatory cells around asbestos deposits.
  • HMGB1 levels in asbestos-exposed individuals were significantly higher than in nonexposed controls (P < 0.0001).
  • Our findings identify the release of HMGB1 as a critical initial step in the pathogenesis of asbestos-related disease, and provide mechanistic links between asbestos-induced cell death, chronic inflammation, and carcinogenesis.
  • Chemopreventive approaches aimed at inhibiting the chronic inflammatory response, and especially blocking HMGB1, may decrease the risk of malignant mesothelioma among asbestos-exposed cohorts.
  • [MeSH-minor] Adenosine Diphosphate Ribose / metabolism. Adenosine Diphosphate Ribose / pharmacology. Animals. Asbestos / metabolism. Asbestos / pharmacology. Carcinogens / metabolism. Carcinogens / pharmacology. Cell Death. Cell Nucleus / metabolism. Cells / metabolism. Cricetinae. Cytokines / metabolism. Cytokines / pharmacology. Epithelial Cells / metabolism. Epithelium / drug effects. Epithelium / metabolism. Female. HMGB Proteins / metabolism. HMGB Proteins / pharmacology. Humans. Hydrogen Peroxide / metabolism. Hydrogen Peroxide / pharmacology. Macrophages / metabolism. Mesocricetus. Mesothelioma / metabolism. Mice. Mice, Inbred BALB C. Necrosis / metabolism. Pleural Neoplasms / metabolism. Poly Adenosine Diphosphate Ribose / pharmacology. Poly(ADP-ribose) Polymerases / metabolism. Poly(ADP-ribose) Polymerases / pharmacology. Reactive Oxygen Species / metabolism. Reactive Oxygen Species / pharmacology. Tumor Necrosis Factor-alpha / metabolism. Tumor Necrosis Factor-alpha / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 1997 Apr 21;185(8):1481-6 [9126928.001]
  • [Cites] Nat Rev Immunol. 2005 Apr;5(4):331-42 [15803152.001]
  • [Cites] Curr Opin Genet Dev. 2005 Oct;15(5):496-506 [16102963.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1564-73 [16221779.001]
  • [Cites] Genes Dev. 2006 Jan 1;20(1):1-15 [16391229.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10397-402 [16798876.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14128-33 [16966607.001]
  • [Cites] Semin Diagn Pathol. 2006 Feb;23(1):56-60 [17044196.001]
  • [Cites] J Leukoc Biol. 2007 Jan;81(1):100-7 [16935945.001]
  • [Cites] Nat Rev Cancer. 2007 Feb;7(2):147-54 [17251920.001]
  • [Cites] Autoimmunity. 2007 Jun;40(4):285-9 [17516211.001]
  • [Cites] J Biol Chem. 2007 Jun 15;282(24):17845-54 [17430886.001]
  • [Cites] Immunol Rev. 2007 Dec;220:35-46 [17979838.001]
  • [Cites] Curr Treat Options Oncol. 2008 Jun;9(2-3):147-57 [18709470.001]
  • [Cites] Cell. 2008 Dec 26;135(7):1161-3 [19109884.001]
  • [Cites] Nat Med. 2010 Apr;16(4):413-9 [20348922.001]
  • [Cites] Cancer Res. 1999 Dec 1;59(23):5922-6 [10606236.001]
  • [Cites] Cytokine. 2000 Aug;12(8):1243-7 [10930305.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10214-9 [10954737.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):191-5 [12110890.001]
  • [Cites] Pharmacol Rev. 2002 Sep;54(3):375-429 [12223530.001]
  • [Cites] Environ Health Perspect. 2002 Oct;110(10):1003-8 [12361925.001]
  • [Cites] EMBO J. 2003 Oct 15;22(20):5551-60 [14532127.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):296-301 [14695889.001]
  • [Cites] Genes Dev. 2004 Jun 1;18(11):1272-82 [15145826.001]
  • [Cites] Int J Oncol. 2004 Jul;25(1):173-8 [15202003.001]
  • [Cites] Nat Rev Immunol. 2004 Aug;4(8):641-8 [15286730.001]
  • [Cites] EMBO Rep. 2004 Aug;5(8):825-30 [15272298.001]
  • [Cites] Semin Cancer Biol. 2004 Dec;14(6):433-9 [15489136.001]
  • [Cites] Cancer Res. 1982 Apr;42(4):1530-6 [6949641.001]
  • [Cites] J Immunol. 1993 May 1;150(9):4188-96 [8473757.001]
  • [Cites] Environ Health Perspect. 1994 Dec;102 Suppl 10:107-10 [7705283.001]
  • [Cites] Occup Environ Med. 1995 May;52(5):316-9 [7795753.001]
  • [Cites] J Clin Invest. 1996 Nov 1;98(9):2050-9 [8903324.001]
  • [Cites] Am J Physiol. 1997 Nov;273(5 Pt 1):L1029-35 [9374731.001]
  • [Cites] Environ Health Perspect. 1997 Sep;105 Suppl 5:1257-60 [9400734.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1839-47 [9846974.001]
  • [Cites] Nat Rev Drug Discov. 2005 May;4(5):421-40 [15864271.001]
  • (PMID = 20616036.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Cytokines; 0 / HMGB Proteins; 0 / HMGB1 Protein; 0 / Reactive Oxygen Species; 0 / Tumor Necrosis Factor-alpha; 1332-21-4 / Asbestos; 20762-30-5 / Adenosine Diphosphate Ribose; 26656-46-2 / Poly Adenosine Diphosphate Ribose; BBX060AN9V / Hydrogen Peroxide; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
  • [Other-IDs] NLM/ PMC2906549
  •  go-up   go-down


39. Canti Z, Scillia R, Cantoni S, Mensi C: [Malignant mesothelioma of the pleura in a truck driver]. Med Lav; 2007 May-Jun;98(3):216-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant mesothelioma of the pleura in a truck driver].
  • BACKGROUND: Among the responsibilities of the health operators in the occupational health and safety services of the local health units in Lombardy (Italy) is the administration of standardized questionnaires for the investigation of possible occupational exposure to asbestos fibres in subjects diagnosed with malignant mesothelioma.
  • OBJECTIVES: To describe a case of malignant mesothelioma in a truck driver suspected of being occupationally exposed to asbestos during the course of administration of the questionnaire.
  • METHODS: Analysis of the literature regarding asbestos contamination of truck cabs.
  • Some years ago Italian authors described a case of asbestosis in a truck-driver and findings of pollution by asbestos fibres in the cabs of some models of trucks.
  • RESULTS: The subject had worked for more than 30 years as a truck driver operating on long distances on truck models described in literature as contaminated by asbestos fibres.
  • He had not transported materials made of asbestos, and had not carried out maintenance on the trucks, nor had he any non-occupational sources of exposure to asbestos.
  • Thus the mesothelioma was related to occupational exposure and procedures were initiated for reporting a suspected occupational disease.
  • [MeSH-major] Asbestos / adverse effects. Automobile Driving. Mesothelioma / etiology. Mineral Fibers / adverse effects. Motor Vehicles. Occupational Diseases / etiology. Pleural Neoplasms / etiology


40. Podobnik J, Kocijancic I, Kovac V, Sersa I: 3T MRI in evaluation of asbestos-related thoracic diseases - preliminary results. Radiol Oncol; 2010 Jun;44(2):92-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 3T MRI in evaluation of asbestos-related thoracic diseases - preliminary results.
  • The aim of this study was to evaluate the diagnostic potential of 3 T MRI as a complementary imaging modality to CT in detecting the pathological changes of asbestos-related thoracic diseases.
  • PATIENTS AND METHODS: Fifteen patients with the asbestos-related thoracic disease were scheduled for 3T MRI.
  • Five had a benign form of the disease and 10 had malignant pleural mesothelioma (MPM).
  • CONCLUSIONS: These preliminary results pointed out that MRI was equal or even better compared with CT examination for detecting possible malignant potential of pleural changes in the asbestos-related pleural disease, using signal intensity measurements of T2 fs-weighted images.
  • The 3T MRI enabled the accurate determination of chest pathology and it could be used for imaging of patients with the asbestos-related thoracic disease.
  • This finding turned us to propose 3T MRI imaging technique as a non-ionizing imaging method for the follow-up of patients with the isolated pleural form of the asbestos-related disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1996 Apr;166(4):963-8 [8610582.001]
  • [Cites] Eur Respir J. 1998 Jan;11(1):194-7 [9543293.001]
  • [Cites] Eur J Radiol. 2000 Jun;34(3):196-207 [10927161.001]
  • [Cites] Acta Radiol. 2001 Sep;42(5):502-7 [11552888.001]
  • [Cites] Radiographics. 2004 Jan-Feb;24(1):105-19 [14730040.001]
  • [Cites] Invest Radiol. 2004 Sep;39(9):554-64 [15308938.001]
  • [Cites] Eur Radiol. 2005 Feb;15(2):324-8 [15565313.001]
  • [Cites] Radiology. 2008 Feb;246(2):596-604 [18056854.001]
  • [Cites] Invest Radiol. 2007 Jun;42(6):377-83 [17507808.001]
  • [Cites] AJR Am J Roentgenol. 2007 Aug;189(2):386-92 [17646465.001]
  • (PMID = 22933897.001).
  • [ISSN] 1318-2099
  • [Journal-full-title] Radiology and oncology
  • [ISO-abbreviation] Radiol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovenia
  • [Other-IDs] NLM/ PMC3423685
  • [Keywords] NOTNLM ; 3T, magnetic resonance imaging / asbestos-related thoracic disease / malignant pleural mesothelioma
  •  go-up   go-down


41. Ray M, Kindler HL: Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest; 2009 Sep;136(3):888-896
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pleural mesothelioma: an update on biomarkers and treatment.
  • Although the insulating properties of asbestos have been known for millennia, the link between asbestos exposure and mesothelioma was not recognized until 1960, when it was first described in South African asbestos miners.
  • The incidence of mesothelioma parallels asbestos usage with a latency of 20 to 40+ years; thus, patient numbers are declining in the United States but rising in the developing world.
  • Newly described biomarkers, including soluble mesothelin-related peptide, megakaryocyte potentiation factor, and osteopontin, may predict which asbestos-exposed individuals will develop mesothelioma, and may prove useful in assessing response to treatment.
  • This combination improves response, survival, time to progression, pulmonary function, and disease-related symptoms.
  • As we learn more about mesothelioma biology, molecularly targeted agents may become treatment options.
  • [MeSH-major] Biomarkers, Tumor / analysis. Mesothelioma / therapy. Pleural Neoplasms / therapy


42. Gaafar R, Bahnassy A, Abdelsalam I, Kamel MM, Helal A, Abdel-Hamid A, Eldin NA, Mokhtar N: Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma. Lung Cancer; 2010 Oct;70(1):43-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma.
  • BACKGROUND: Malignant pleural mesothelioma (MPM) is an asbestos related aggressive tumor.
  • Asbestos causes genetic modifications and cell signaling events that favor resistance to chemotherapy.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Mesothelioma / enzymology. Pleural Neoplasms / enzymology. Receptor, Epidermal Growth Factor / biosynthesis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20347505.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


43. Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K: Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. Lung Cancer; 2008 Aug;61(2):235-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
  • Soluble mesothelin-related protein (SMRP) in serum is potentially a sensitive marker of malignant mesothelioma (MM) diagnosis and progression, and may be useful as screening marker.
  • Levels of SMRP, CA125 and CYFRA 21-1 in pre-diagnostic (1-30 years) serum samples from 47 mesothelioma cases and 141 matched controls were analysed.
  • The association between biomarker level and mesothelioma risk and survival was analysed, adjusting for asbestos exposure.
  • Survival related to tumor mesothelin expression, age, sex, histological type, location, asbestos exposure and pre-clinical SMRP was analysed.
  • There was no significant association between biomarker levels and mesothelioma risk when analysed as continuous variables or as tertiles.
  • Biomarker levels <10, 10-19 and >or=20 years before diagnosis were not significantly associated to mesothelioma risk.
  • Mesothelin expression in <50% of tumor cells was a significant negative prognostic marker in all cases of malignant mesothelioma (median survival=6 months vs. 12 months, hazard ratio (HR)=2.49, 95%CI 1.17-5.27), and also when only epithelial mesothelioma was analysed (median=6 months vs. 14 months, HR=2.36, 95%CI 1.07-5.22).
  • High age (>65 years) was an independent negative prognostic factor that was related to both mesothelin expression and asbestos exposure.
  • Mesothelioma of the epithelial type of the peritoneum had a significantly longer survival than epithelial type in pleura and was also related to mesothelin expression.
  • [MeSH-major] Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. Keratins / blood. Membrane Glycoproteins / blood. Mesothelioma / diagnosis. Peritoneal Neoplasms / diagnosis. Pleural Neoplasms / diagnosis. Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Age Factors. Asbestos / adverse effects. Case-Control Studies. Child. Child, Preschool. Female. GPI-Linked Proteins. Humans. Infant. Keratin-19. Male. Occupational Exposure / adverse effects. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281122.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Keratin-19; 0 / Membrane Glycoproteins; 0 / NBR1 protein, human; 0 / Proteins; 0 / antigen CYFRA21.1; 0 / mesothelin; 1332-21-4 / Asbestos; 68238-35-7 / Keratins
  •  go-up   go-down


44. Bolognesi C, Martini F, Tognon M, Filiberti R, Neri M, Perrone E, Landini E, Canessa PA, Ivaldi GP, Betta P, Mutti L, Puntoni R: A molecular epidemiology case control study on pleural malignant mesothelioma. Cancer Epidemiol Biomarkers Prev; 2005 Jul;14(7):1741-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A molecular epidemiology case control study on pleural malignant mesothelioma.
  • Pleural malignant mesothelioma is an uncommon neoplasm usually associated with asbestos exposure.
  • The increasing incidence of malignant mesothelioma cases involving individuals with low levels of asbestos exposure suggests a complex carcinogenetic process with the involvement of other cofactors.
  • A biomonitoring study was carried out to evaluate the micronuclei frequency in PBLs of patients with pleural malignant mesothelioma with respect to lung cancer, healthy, and risk controls as a marker of cancer susceptibility in correlation with the presence of SV40.
  • A significant increased micronuclei frequency was observed in patients with malignant mesothelioma in comparison with all the other groups, the mean micronuclei frequency was double in patients with malignant mesothelioma compared with healthy controls, risk controls, and patients with lung adenocarcinoma (median 11.4 binucleated cells with micronuclei/1,000 binucleated cells versus 6.2, 6.1, and 5.1, respectively).
  • Evidence of cytogenetic damage revealed as micronuclei frequency in mesothelioma cancer patients could be related to exogenous and endogenous cofactors besides asbestos exposure.
  • [MeSH-major] Asbestos / adverse effects. Lung Neoplasms / genetics. Mesothelioma / etiology. Molecular Epidemiology. Pleural Neoplasms / etiology. Smoking / adverse effects

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Smoking.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16030111.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


45. Park EK, Sandrini A, Yates DH, Creaney J, Robinson BW, Thomas PS, Johnson AR: Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am J Respir Crit Care Med; 2008 Oct 15;178(8):832-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.
  • RATIONALE: Soluble mesothelin-related protein (SMRP) is raised in epithelial-type malignant mesothelioma (MM), but the utility of SMRP in screening for MM is unknown.
  • OBJECTIVES: We aimed to evaluate SMRP in an asbestos-exposed cohort.
  • MEASUREMENTS AND MAIN RESULTS: Mean (+/-SD) SMRP in healthy subjects exposed to asbestos (n = 223) was 0.79 (+/-0.45) nM.
  • CONCLUSIONS: This is the first large-scale prospective study of SMRP for screening for malignancy in asbestos-exposed individuals.
  • [MeSH-major] Asbestos / adverse effects. Membrane Glycoproteins / biosynthesis. Mesothelioma / diagnosis. Occupational Diseases / diagnosis. Occupational Exposure / adverse effects. Pleural Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Respir Crit Care Med. 2008 Oct 15;178(8):781-2 [18832552.001]
  • [CommentIn] Am J Respir Crit Care Med. 2009 May 1;179(9):851; author reply 851-852 [19383930.001]
  • (PMID = 18583574.001).
  • [ISSN] 1535-4970
  • [Journal-full-title] American journal of respiratory and critical care medicine
  • [ISO-abbreviation] Am. J. Respir. Crit. Care Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 1332-21-4 / Asbestos
  •  go-up   go-down


46. Martínez González C, Cruz Carmona MJ: [Update in respiratory disease and environmental exposure: an invisible relationship]. Arch Bronconeumol; 2009;45 Suppl 1:21-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the case of neoplastic diseases associated with asbestos inhalation, the areas of most interest have been in the search for tumour markers, the importance of the determination of asbestos fibre deposits in biological samples, and new therapeutic schemes in malignant pleural mesothelioma.
  • A consensus article has been published on occupational asthma, in which some clinical evidenced-based recommendations are established, directed at the diagnosis and management of work-related asthma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19303526.001).
  • [ISSN] 0300-2896
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


47. McCoy MJ, Nowak AK, Lake RA: Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma. Tissue Antigens; 2009 Jul;74(1):1-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma.
  • Whether the immune system can recognize malignant and premalignant cells and eliminate them to prevent the development of cancer is still a matter of open debate, but in our view, the balance of evidence favours this concept.
  • Malignant mesothelioma has traditionally been considered a relatively non-immunogenic cancer.
  • However, mesothelioma cells do express a set of well-defined tumour antigens that have been shown to engage with the host immune system.
  • Mesothelioma should therefore be considered a target for immunotherapy.
  • A variety of anticancer immunotherapies have been investigated in mesothelioma and in other malignancies, although these have been largely ineffective when used in isolation.
  • Here, we discuss the rationale behind combining these two, long considered antagonistic, treatment options in the context of malignant mesothelioma.
  • [MeSH-major] Antigens, Neoplasm / immunology. Antineoplastic Agents / therapeutic use. Immunosuppression. Mesothelioma / therapy. Neoplasms, Mesothelial / therapy


48. Harding AH, Darnton A, Wegerdt J, McElvenny D: Mortality among British asbestos workers undergoing regular medical examinations (1971-2005). Occup Environ Med; 2009 Jul;66(7):487-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality among British asbestos workers undergoing regular medical examinations (1971-2005).
  • OBJECTIVES: The Great Britain Asbestos Survey was established to monitor mortality among workers covered by regulations to control occupational exposure to asbestos.
  • This study updates the estimated burden of asbestos-related mortality in the cohort, and identifies risk factors associated with mortality.
  • The SMR for all cause mortality was 141 (95% CI 139 to 143) and for all malignant neoplasms 163 (95% CI 159 to 167).
  • The SMRs for cancers of the stomach (166), lung (187), peritoneum (3730) and pleura (968), mesothelioma (513), cerebrovascular disease (164) and asbestosis (5594) were statistically significantly elevated, as were the corresponding PMRs.
  • In age and sex adjusted analysis, birth cohort, age at first exposure, year of first exposure, duration of exposure, latency and job type were associated with the relative risk of lung, pleural and peritoneal cancers, asbestosis and mesothelioma mortality.
  • CONCLUSIONS: Known associations between asbestos exposure and mortality from lung, peritoneal and pleural cancers, mesothelioma and asbestosis were confirmed, and evidence of associations with stroke and stomach cancer mortality was observed.
  • Limited evidence suggested that asbestos-related disease risk may be lower among those first exposed in more recent times.
  • [MeSH-major] Asbestos / toxicity. Neoplasms / mortality. Occupational Diseases / mortality. Occupational Exposure / adverse effects

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Occup Environ Med. 2009 Dec;66(12):854-5 [19934119.001]
  • (PMID = 19254909.001).
  • [ISSN] 1470-7926
  • [Journal-full-title] Occupational and environmental medicine
  • [ISO-abbreviation] Occup Environ Med
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


49. Antonescu-Turcu AL, Schapira RM: Parenchymal and airway diseases caused by asbestos. Curr Opin Pulm Med; 2010 Mar;16(2):155-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parenchymal and airway diseases caused by asbestos.
  • PURPOSE OF REVIEW: The extensive industrial use of asbestos for many decades has been linked to development of benign and malignant pleuropulmonary disease.
  • This review summarizes newer evidence and ongoing controversies that exist in the literature regarding asbestos-related parenchymal and airway diseases.
  • RECENT FINDINGS: Asbestosis represents a significant respiratory problem despite the improvement in the workplace hygiene and a decrease in use of asbestos.
  • The role of asbestos exposure alone as a cause of chronic airway obstruction remains uncertain.
  • The relationship between lung cancer and asbestos exposure alone and in combination with smoking has also been investigated.
  • The benefit of screening for asbestos-related pleuropulmonary disease remains uncertain as does the use of computed tomography scanning for the purpose of screening.
  • SUMMARY: Future studies will help clarify the clinical issues and shape screening strategies for asbestos-exposed individuals.
  • [MeSH-major] Asbestos / adverse effects. Asbestosis / etiology. Lung Diseases / chemically induced
  • [MeSH-minor] Humans. Lung Diseases, Obstructive / chemically induced. Lung Diseases, Obstructive / radiography. Lung Neoplasms / chemically induced. Lung Neoplasms / radiography. Mesothelioma / chemically induced. Mesothelioma / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20104177.001).
  • [ISSN] 1531-6971
  • [Journal-full-title] Current opinion in pulmonary medicine
  • [ISO-abbreviation] Curr Opin Pulm Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  • [Number-of-references] 34
  •  go-up   go-down


50. Schneider J, Bernges U: CYP1A1 and CYP1B1 polymorphisms as modifying factors in patients with pneumoconiosis and occupationally related tumours: A pilot study. Mol Med Rep; 2009 Nov-Dec;2(6):1023-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CYP1A1 and CYP1B1 polymorphisms as modifying factors in patients with pneumoconiosis and occupationally related tumours: A pilot study.
  • The effect of CYP1A1 and CYP1B1 polymorphisms as genetic modifiers of risk was investigated in individuals with asbestos, silica dust or ionizing radiation-induced occupational tumours compared to exposed non-cancer subjects suffering from pneumoconiosis, particularly in relation to tobacco smoking.
  • CYP1A1 T6235C, CYP1A1 A4889G and CYP1B1 codon 432 polymorphisms were determined by real-time PCR analysis in patients with asbestos-related lung cancer (n=39), patients with diffuse malignant mesotheliomas (n=19), lung cancer in silicosis patients (n=7), uranium miners with lung cancer (UMLC) (n=40), patients with asbestosis (n=181), and silicosis patients (n=204).
  • The risk for patients with the susceptible CYP1A1 A4889G allele was calculated as being between OR=0.39 (95% CI 0.10-1.54) for mesothelioma patients and OR=1.54 (95% CI 0.49-4.89) for UMLC.
  • CYP1B1 Val432Leu polymorphisms were associated with a risk of OR=0.56 (95% CI 0.2-1.55) for UMLC and OR=1.52 (95% CI 0.68-3.39) for asbestos-exposed lung cancer patients.
  • In this pilot study, the analyzed polymorphism had no consistent modifying effect on pneumoconiosis or occupationally related tumours.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21475938.001).
  • [ISSN] 1791-3004
  • [Journal-full-title] Molecular medicine reports
  • [ISO-abbreviation] Mol Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


51. Gaafar RM, Eldin NH: Epidemic of mesothelioma in Egypt. Lung Cancer; 2005 Jul;49 Suppl 1:S17-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemic of mesothelioma in Egypt.
  • Asbestos has been recognized in Egypt since a long time as ancient Egyptians were using it in mummification.
  • Mesothelioma in Egypt is mainly attributed to environmental origin with a high incidence of women and young adults affected.
  • The incidence of mesothelioma is rising in Egypt.
  • Epidemiological data for 635 malignant mesothelioma (MM) patients over 4 years in the third Millennium were collected from the National Cancer Institute (NCI), Cairo University and Abbassia Chest hospital.
  • A clinicopathological study was done for 100 malignant pleural mesothelioma (MPM) patients and showed that asbestos exposure and SV40 positivity were evident in 67% and 60% of cases, respectively.
  • Evaluation of p53 and pRb immunohistochemically showed that pRb alteration was related to poor survival.
  • Asbestos in Cairo is a silent killer and measures toward eliminating it entirely or at least strictly controlling human contact with this dangerous carcinogen have to be taken in order to combat the coming epidemic of mesothelioma in Egypt.
  • [MeSH-major] Asbestos / adverse effects. Disease Outbreaks. Mesothelioma / epidemiology. Pleural Neoplasms / epidemiology


52. Putzu MG, Bruno C, Zona A, Massiccio M, Pasetto R, Piolatto PG, Comba P: Fluoro-edenitic fibres in the sputum of subjects from Biancavilla (Sicily): a pilot study. Environ Health; 2006;5:20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: An excess of mortality for malignant neoplasms of the pleura in Biancavilla, promoted an investigation for pleural mesothelioma, disclosing 17 cases.
  • As the absence of known sources of asbestos exposure, a local stone quarry, located near the inhabited area, used for the extraction of building materials, was investigated.
  • METHODS: Hypothesizing a behaviour of the new fibre analogous to that of asbestos, the determination of the free fibres and the ferruginous bodies in spontaneous sputum was carried out.
  • RESULTS: The preliminary findings are related to 12 subjects (7 females and 5 males).
  • CONCLUSION: The occurrence of the pleural mesothelioma cases and the presence of fluoro-edenitic fibres in spontaneous sputum, evidence the need to study the biological activity of fluoro-edenitic fibres and the implementation of epidemiological monitoring systems.
  • [MeSH-major] Environmental Exposure. Mesothelioma / etiology. Mineral Fibers / adverse effects. Mineral Fibers / analysis. Pleural Neoplasms / etiology
  • [MeSH-minor] Asbestos, Amphibole / adverse effects. Asbestos, Amphibole / analysis. Female. Fluorine. Geological Phenomena. Geology. Humans. Italy. Male. Middle Aged. Sputum / chemistry

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. FLUORINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Environ Health. 2000 Nov-Dec;55(6):392-8 [11128876.001]
  • [Cites] Sci Total Environ. 2004 Jun 5;325(1-3):51-8 [15144777.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 15;98(6):414-7 [16537834.001]
  • [Cites] Occup Environ Med. 2005 Sep;62(9):656 [16109823.001]
  • [Cites] Eur Respir J. 1998 Jun;11(6):1416-26 [9657589.001]
  • [Cites] Scand J Work Environ Health. 1997 Feb;23(1):48-53 [9098912.001]
  • [Cites] Med Lav. 1996 Jul-Aug;87(4):283-8 [8956540.001]
  • [Cites] Eur Respir J. 1996 Apr;9(4):680-6 [8726931.001]
  • [Cites] Mod Pathol. 1989 Jul;2(4):320-2 [2548182.001]
  • [Cites] Lab Invest. 1981 May;44(5):420-5 [6262566.001]
  • [Cites] Acta Cytol. 1980 Sep-Oct;24(5):460-5 [7001827.001]
  • [Cites] Scand J Work Environ Health. 2004 Jun;30(3):249-52 [15250654.001]
  • [Cites] Eur Respir J. 2002 Nov;20(5):1167-73 [12449170.001]
  • [Cites] Arch Environ Health. 2003 Apr;58(4):229-32 [14655903.001]
  • [Cites] Toxicol In Vitro. 2006 Sep;20(6):841-50 [16480849.001]
  • (PMID = 16780574.001).
  • [ISSN] 1476-069X
  • [Journal-full-title] Environmental health : a global access science source
  • [ISO-abbreviation] Environ Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Asbestos, Amphibole; 0 / Mineral Fibers; 284SYP0193 / Fluorine
  • [Other-IDs] NLM/ PMC1557492
  •  go-up   go-down


53. Kricka O, Matanić Lender D, Barković I, Flego V, Kupanovac Z, Bulat Kardum L: [Malignant pleural mesothelioma in patients hospitalised at the Clinical Hospital Centre Rijeka between 1989 and 2008]. Arh Hig Rada Toksikol; 2009 Nov;60 Suppl:41-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant pleural mesothelioma in patients hospitalised at the Clinical Hospital Centre Rijeka between 1989 and 2008].
  • Malignant pleural mesothelioma (MPM) is a relatively rare tumour, mainly associated with occupational exposure to asbestos.
  • Occupational exposure to asbestos was established in 72 patients who worked in shipbuilding.
  • We believe that this is not related to improved diagnostics, but to the long latency of the disease.
  • In the U.S.A. and Europe, MPM incidence is expected to peak by 2020, while in countries with poor control over asbestos use this may take longer.
  • [MeSH-major] Asbestos / adverse effects. Mesothelioma / epidemiology. Occupational Diseases / epidemiology. Pleural Neoplasms / epidemiology


54. Hollevoet K, Nackaerts K, Thimpont J, Germonpré P, Bosquée L, De Vuyst P, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP: Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med; 2010 Mar 15;181(6):620-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
  • RATIONALE: Soluble mesothelin (SM) is currently the reference serum biomarker of malignant pleural mesothelioma (MPM).
  • METHODS: A total of 507 participants were enrolled in six cohorts: healthy control subjects (n = 101), healthy asbestos-exposed individuals (n = 89), and patients with benign asbestos-related disease (n = 123), benign respiratory disease (n = 46), lung cancer (n = 63), and MPM (n = 85).
  • [MeSH-major] Biomarkers, Tumor / blood. Membrane Glycoproteins / blood. Mesothelioma / blood. Mesothelioma / diagnosis. Pleural Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20075387.001).
  • [ISSN] 1535-4970
  • [Journal-full-title] American journal of respiratory and critical care medicine
  • [ISO-abbreviation] Am. J. Respir. Crit. Care Med.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


55. Aigner C, Hoda MA, Lang G, Taghavi S, Marta G, Klepetko W: Outcome after extrapleural pneumonectomy for malignant pleural mesothelioma. Eur J Cardiothorac Surg; 2008 Jul;34(1):204-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.
  • BACKGROUND: Malignant pleural mesothelioma is a mainly asbestos-related neoplasm that occurs with increasing frequency and is associated with a poor prognosis.
  • We therefore analysed our experience with extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma.
  • METHODS: We retrospectively reviewed our institutional experience with all consecutive patients undergoing extrapleural pneumonectomy for malignant pleural mesothelioma from 1994 to 2005.
  • CONCLUSION: Extrapleural pneumonectomy as part of a multi-modality treatment regimen is a good treatment option for selected patients with malignant pleural mesothelioma.
  • [MeSH-major] Mesothelioma / surgery. Pleural Neoplasms / surgery. Pneumonectomy / methods

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18407510.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


56. Edakuni N, Ikuta K, Yano S, Nakataki E, Muguruma H, Uehara H, Tani M, Yokota J, Aizawa H, Sone S: Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice. Oncol Res; 2006;16(5):235-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.
  • Malignant pleural mesothelioma (MPM) is closely related to exposure to asbestos, and a rapid increase in the number of MPM patients is therefore estimated to occur from 2010 to 2040 in Japan.
  • The inactivation of the MYO18B gene plays an important role in several malignant diseases.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / genetics. Lung Neoplasms / genetics. Mesothelioma / genetics. Myosins / genetics. Myosins / pharmacology. Pleural Effusion / genetics. Pleural Neoplasms / genetics. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / pharmacology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17294804.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYO18B protein, human; 0 / Tumor Suppressor Proteins; EC 3.6.4.1 / Myosins
  •  go-up   go-down


57. Heyer CM, Theile A, Weisser H, Reichert J, Horch C, Mueller KM, Bauer TT: Subarachnoid-pleural fistula as a complication of malignant pleural mesothelioma. Respirology; 2006 Jul;11(4):502-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subarachnoid-pleural fistula as a complication of malignant pleural mesothelioma.
  • We report a 62-year-old male patient with asbestos-related malignant pleural mesothelioma who developed recurrent pleural effusions after surgical resection of paravertebral tumour masses.
  • Cytological studies of the pleural fluid showed no evidence of inflammatory or malignant cells.
  • A subarachnoid-pleural fistula has to be included in the differential diagnosis of patients with recurrent pleural effusions after surgical debulkment of malignant pleural mesothelioma.
  • [MeSH-major] Fistula / complications. Mesothelioma / pathology. Pleural Cavity / radiography. Pleural Neoplasms / pathology. Subarachnoid Space

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Fistulas.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16771925.001).
  • [ISSN] 1323-7799
  • [Journal-full-title] Respirology (Carlton, Vic.)
  • [ISO-abbreviation] Respirology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Lipocalins; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.2 / prostaglandin R2 D-isomerase
  •  go-up   go-down


58. Rodríguez Portal JA, Rodríguez Becerra E, Rodríguez Rodríguez D, Alfageme Michavila I, Quero Martínez A, Diego Roza C, León Jiménez A, Isidro Montes I, Cebollero Rivas P: Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev; 2009 Feb;18(2):646-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
  • BACKGROUND: Malignant pleural mesothelioma (MPM) results from malignant transformation of mesothelial cells.
  • Past asbestos exposure represents a major risk factor for MPM and other benign pleural disease.
  • Soluble mesothelin-related peptides (SMRP) have been regarded as a promising serum biomarker for MPM.
  • The aim of this study was to investigate serum levels of SMRP in malignant and nonmalignant asbestos-related pleural disease.
  • PATIENTS: Four groups of patients were investigated: group 1 composed of 48 healthy subjects, group 2 composed of 177 patients with previous asbestos exposure and no pleural disease, group 3 composed of 36 patients with MPM, and group 4 composed of 101 patients with previous asbestos exposure and benign pleural disease.
  • Subjects exposed to asbestos had higher SMRP concentrations than normal control subjects regardless of the presence of pleural disease.
  • CONCLUSIONS: These data attest to good diagnostic sensitivity and specificity of SMRP for the diagnosis of malignant mesothelioma.
  • We have also shown that serum SMRP levels might serve as a marker of asbestos exposure.
  • [MeSH-major] Asbestosis / blood. Biomarkers, Tumor / blood. Membrane Glycoproteins / blood. Mesothelioma / blood. Pleural Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190155.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


59. Miles SE, Sandrini A, Johnson AR, Yates DH: Clinical consequences of asbestos-related diffuse pleural thickening: A review. J Occup Med Toxicol; 2008;3:20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical consequences of asbestos-related diffuse pleural thickening: A review.
  • Asbestos-related diffuse pleural thickening (DPT), or extensive fibrosis of the visceral pleura secondary to asbestos exposure, is increasingly common due to the large number of workers previously exposed to asbestos.
  • It may coexist with asbestos related pleural plaques but has a distinctly different pathology.
  • Generation of reactive oxygen and nitrogen species, profibrotic cytokines and growth factors in response to asbestos is likely to play a role in the formation of a fibrinous intrapleural matrix.
  • Benign asbestos related pleural effusions commonly antedate the development of diffuse pleural thickening.
  • Environmental as well as occupational exposure to asbestos may also result in pleural fibrosis, particularly in geographic areas with naturally occurring asbestiform soil minerals.
  • High resolution computed tomography (CT) is more sensitive and specific than chest radiography for the diagnosis of diffuse pleural thickening, and several classification systems for asbestos-related disorders have been devised.
  • Magnetic resonance imaging and fluorodeoxyglucose positron emission tomography (PET) scanning may be useful in distinguishing between DPT and malignant mesothelioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Rev Respir Dis. 1987 Dec;136(6):1429-34 [2825569.001]
  • [Cites] Radiographics. 1989 May;9(3):523-51 [2727359.001]
  • [Cites] AJR Am J Roentgenol. 1988 Nov;151(5):883-91 [3263018.001]
  • [Cites] Br J Ind Med. 1988 Jul;45(7):443-9 [3260799.001]
  • [Cites] Occup Med. 1987 Apr-Jun;2(2):383-407 [3303386.001]
  • [Cites] Am Rev Respir Dis. 1984 Nov;130(5):884-7 [6497167.001]
  • [Cites] Eur J Respir Dis. 1987 Aug;71(2):113-21 [3622660.001]
  • [Cites] AJR Am J Roentgenol. 1985 Jan;144(1):9-18 [3871154.001]
  • [Cites] Ann Occup Hyg. 1985;29(3):305-55 [4073702.001]
  • [Cites] AJR Am J Roentgenol. 1990 Mar;154(3):487-92 [2106209.001]
  • [Cites] Respir Med. 1990 Mar;84(2):129-34 [2371434.001]
  • [Cites] Ann Occup Hyg. 1984;28(1):1-12 [6326648.001]
  • [Cites] Occup Environ Med. 2007 Nov;64(11):747-52 [17449562.001]
  • [Cites] J Thorac Cardiovasc Surg. 2006 Oct;132(4):763-8 [17000285.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Jun;129(6):1364-70 [15942579.001]
  • [Cites] Respirology. 2004 Nov;9(4):441-7 [15612954.001]
  • [Cites] Occup Environ Med. 2003 Jan;60(1):35-41; discussion 41-2 [12499455.001]
  • [Cites] Int Arch Occup Environ Health. 2002 Apr;75(4):224-8 [11981655.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):26-35 [11836666.001]
  • [Cites] Chin Med J (Engl). 2001 Jun;114(6):645-9 [11780445.001]
  • [Cites] Respiration. 2001;68(5):533-6 [11694819.001]
  • [Cites] Scand J Work Environ Health. 2001 Apr;27(2):154-5 [11409599.001]
  • [Cites] Radiology. 2001 Jul;220(1):237-43 [11426004.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Mar;163(3 Pt 1):640-4 [11254517.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Nov;162(5):1807-11 [11069817.001]
  • [Cites] Chest. 2000 Sep;118(3):604-9 [10988179.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Jul;162(1):98-104 [10903227.001]
  • [Cites] Clin Radiol. 2000 Jun;55(6):422-32 [10873686.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1507-15 [10556113.001]
  • [Cites] Respirology. 2004 Nov;9(4):428-40 [15612953.001]
  • [Cites] Chest. 2004 Dec;126(6):1994-9 [15596704.001]
  • [Cites] Thorax. 1999 Jul;54(7):638-52 [10377212.001]
  • [Cites] Chest. 1998 Sep;114(3):713-22 [9743156.001]
  • [Cites] Clin Chest Med. 1998 Jun;19(2):311-29 [9646983.001]
  • [Cites] Eur Respir J. 1998 May;11(5):1021-7 [9648950.001]
  • [Cites] J Clin Invest. 1998 Jul 15;102(2):445-54 [9664087.001]
  • [Cites] Am J Ind Med. 1996 Sep;30(3):241-51 [8876791.001]
  • [Cites] Thorax. 1996 Feb;51(2):210-6 [8711661.001]
  • [Cites] Am J Respir Crit Care Med. 1996 Jan;153(1):301-6 [8542134.001]
  • [Cites] Occup Environ Med. 1994 Jul;51(7):456-60 [8044244.001]
  • [Cites] Chest. 1994 Jun;105(6):1748-52 [8205871.001]
  • [Cites] Br J Ind Med. 1993 Oct;50(10):902-6 [8217849.001]
  • [Cites] Eur Respir J. 1993 Jul;6(7):978-82 [8396536.001]
  • [Cites] Br J Ind Med. 1991 Nov;48(11):762-70 [1659443.001]
  • [Cites] Am Rev Respir Dis. 1991 Feb;143(2):408-22 [1990961.001]
  • [Cites] Chest. 1991 Jan;99(1):191-8 [1984952.001]
  • [Cites] Am Rev Respir Dis. 1990 Oct;142(4):837-42 [2221591.001]
  • [Cites] Br J Dis Chest. 1983 Oct;77(4):321-43 [6357260.001]
  • [Cites] Am J Med. 1983 Dec;75(6):911-9 [6650544.001]
  • [Cites] Eur J Respir Dis. 1980 Jun;61(3):129-38 [7002573.001]
  • [Cites] JAMA. 1982 Feb 5;247(5):617-22 [7054563.001]
  • [Cites] IARC Sci Publ. 1980;(30):237-46 [7239642.001]
  • [Cites] Thorax. 1980 Aug;35(8):564-9 [7444823.001]
  • [Cites] Thorax. 1980 Jan;35(1):31-6 [7361282.001]
  • [Cites] Chest. 1973 Aug;64(2):193-6 [4725075.001]
  • [Cites] Ann N Y Acad Sci. 1965 Dec 31;132(1):351-67 [5219560.001]
  • [Cites] Br J Dis Chest. 1966 Jan;60(1):19-22 [5920504.001]
  • [Cites] Radiology. 2004 Oct;233(1):182-90 [15333769.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Sep 15;170(6):691-715 [15355871.001]
  • [Cites] Invest Radiol. 2004 Sep;39(9):554-64 [15308938.001]
  • [Cites] Chest. 2004 Mar;125(3):1103-17 [15006974.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Jul;126(1):11-6 [12878934.001]
  • [Cites] Scand J Work Environ Health. 2003 Feb;29(1):60-3 [12630437.001]
  • (PMID = 18775081.001).
  • [ISSN] 1745-6673
  • [Journal-full-title] Journal of occupational medicine and toxicology (London, England)
  • [ISO-abbreviation] J Occup Med Toxicol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2553409
  •  go-up   go-down


60. Proietti L, Spicuzza L, Di Maria A, Polosa R, Sebastian Torres E, Asero V, Di Maria GU: Non-occupational malignant pleural mesothelioma due to asbestos and non-asbestos fibres. Monaldi Arch Chest Dis; 2006 Dec;65(4):210-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-occupational malignant pleural mesothelioma due to asbestos and non-asbestos fibres.
  • BACKGROUND AND AIM: The occurrence of malignant pleural mesothelioma (MPM) has been reported among population groups with no documented professional exposure to asbestos fibres living in different geographic areas.
  • This paper reviews existing data related to non occupational MPM including its occurrence in the province of Catania (Sicily, Italy).
  • METHODS: An electronic search of literature related to non occupational MPM was performed including the year 2005.
  • RESULTS: Non occupational MPM in subjects living in areas contaminated by a variety of asbestos and non asbestos fibres has been well documented through a number of epidemiologic studies including cases series, case-control studies, and a cohort study.
  • CONCLUSION: It is likely that genetic predisposition and non-occupational exposure to low doses of asbestos and asbestos-like fibres may concur to the development of malignant mesothelioma.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17393666.001).
  • [ISSN] 1122-0643
  • [Journal-full-title] Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace
  • [ISO-abbreviation] Monaldi Arch Chest Dis
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Mineral Fibers; 1332-21-4 / Asbestos
  • [Number-of-references] 86
  •  go-up   go-down


61. Candura SM, Canto A, Amatu A, Gerardini M, Stella G, Mensi M, Poggi G: Malignant mesothelioma of the tunica vaginalis testis in a petrochemical worker exposed to asbestos. Anticancer Res; 2008 Mar-Apr;28(2B):1365-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma of the tunica vaginalis testis in a petrochemical worker exposed to asbestos.
  • Malignant mesothelioma of the tunica vaginalis testis is a rare and aggressive asbestos-related malignancy that may pose difficult diagnostic problems.
  • After 16 years of asbestos exposure, a 38-year-old petrochemical worker came to our notice with acute right testicular pain and swelling, simulating torsion of the spermatic cord.
  • Immunohistochemical staining for the epithelial glycoprotein Ber-EP4 was negative, whereas results were positive for mesothelial markers, thus leading to the diagnosis of epithelial mesothelioma.
  • Tunical mesothelioma may simulate metastatic carcinoma at routine histopathological examination.
  • Immunohistochemistry and occupational anamnesis are helpful for the correct diagnosis, which, in turn, is important for prognosis and treatment, and in relation to legal issues when asbestos is involved in the causation of the disease.
  • [MeSH-major] Asbestos / poisoning. Chemical Industry. Mesothelioma / etiology. Occupational Diseases / etiology. Occupational Exposure / adverse effects. Testicular Neoplasms / etiology


62. Aceto N, Bertino P, Barbone D, Tassi G, Manzo L, Porta C, Mutti L, Gaudino G: Taurolidine and oxidative stress: a rationale for local treatment of mesothelioma. Eur Respir J; 2009 Dec;34(6):1399-407
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Taurolidine and oxidative stress: a rationale for local treatment of mesothelioma.
  • Malignant mesothelioma is an asbestos-related, aggressive tumour, resistant to most anticancer therapies.
  • Akt is a key mediator of mesothelioma cell survival and chemoresistance.
  • This study aimed to clarify the mechanism by which taurolidine (TN), a known synthetic compound with antimicrobial and antineoplastic properties, leads to mesothelioma cell death.
  • TN induces cell death of mesothelioma cells, but not of non-neoplastic human mesothelial cells.
  • After TN treatment of mesothelioma cells, Akt but not extracellular signal-regulated kinase (Erk) 1/2 activity is inhibited a in time- and dose-dependent manner.
  • TN induces mesothelioma cell death via oxidative stress, accompanied by inhibition of Akt signalling.
  • This provides a promising molecular rationale for TN as local treatment of malignant mesothelioma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Mesothelioma / drug therapy. Mesothelioma / pathology. Oxidative Stress. Taurine / analogs & derivatives. Thiadiazines / therapeutic use


63. Ascoli V, Cavone D, Merler E, Barbieri PG, Romeo L, Nardi F, Musti M: Mesothelioma in blood related subjects: report of 11 clusters among 1954 Italy cases and review of the literature. Am J Ind Med; 2007 May;50(5):357-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelioma in blood related subjects: report of 11 clusters among 1954 Italy cases and review of the literature.
  • BACKGROUND: Malignant mesothelioma is a sporadic tumor related to asbestos.
  • METHODS: The study analyses the features of mesothelioma in blood relatives that might explain the disease clustering.
  • Data sources of familial clusters were three population-based Mesothelioma Registries in Italy (Veneto and Apulia Regions, Brescia province; 1978-2005) and Medline, Toxline, and Oshline/Hseline databases for a review of the literature (1968-2006).
  • RESULTS: Eleven clusters (22 cases) were identified among 1954 Italy mesothelioma cases, and 51 clusters (120 cases) were extracted from 33 studies.
  • The proportion of Italy familial cases was 1.4 per 100 mesothelioma cases; the ratio between the number of familial clusters and the number of non-familial mesothelioma cases was 1:148.
  • The mesothelioma profile in consanguineous is the same as in non-consanguineous subjects (male prevalence; pleural site; age at diagnosis >50 years; asbestos exposure).
  • Most clusters occurred in asbestos workers (shipyard, asbestos-cement production/processing, and insulation) and household-exposed blood relatives.
  • Others were related to asbestos-cement factory pollution, asbestos-in-place, and handling asbestos-contaminated textiles.
  • CONCLUSIONS: Available data support asbestos exposure as the main risk factor in mesothelioma cases among blood relatives.
  • Our finding of a low proportion of familial cases would not suggest the influence of a large genetic component for mesothelioma in blood relatives.
  • [MeSH-major] Asbestos / toxicity. Environmental Exposure / adverse effects. Mesothelioma / genetics. Occupational Exposure / adverse effects


64. Dainese E, Pozzi B, Milani M, Rossi G, Pezzotta MG, Vertemati G, Tricomi P, Sessa F: Primary pleural epithelioid angiosarcoma. A case report and review of the literature. Pathol Res Pract; 2010 Jun 15;206(6):415-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant vascular tumors are uncommon sarcomas that arise from endothelial cells of small blood vessels and may affect every organ.
  • Even if etiological factors implicated in the development of vascular sarcomas are still unclear, the strongest association with the disease was a history of chronic tuberculous pyothorax, observed only in Japanese patients, while prior radiotherapy and occupational exposure to asbestos have been reported in few Western cases.
  • Histological features and clinical presentation often cause several problems in the differential diagnosis, particularly with mesothelioma and metastasis from poorly differentiated carcinomas.
  • Immunohistochemistry plays an important role in identifying these rare entities, confirming the endothelial origin of the neoplasm with the expression of at least one of the vascular markers CD31, CD34, or factor VIII-related antigen.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diabetes Mellitus, Type 2. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Mesothelioma / pathology. Middle Aged. Neoplasm Metastasis / pathology. Radiculopathy / complications

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 20089367.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 53
  •  go-up   go-down


65. De Bruin ML, Burgers JA, Baas P, van 't Veer MB, Noordijk EM, Louwman MW, Zijlstra JM, van den Berg H, Aleman BM, van Leeuwen FE: Malignant mesothelioma after radiation treatment for Hodgkin lymphoma. Blood; 2009 Apr 16;113(16):3679-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma after radiation treatment for Hodgkin lymphoma.
  • Malignant mesothelioma is a relatively uncommon malignancy.
  • Although the pathogenesis is primarily related to asbestos, the disease may be associated with radiation exposure.
  • Recently, increased risks for second primary mesothelioma after radiation for lymphoma have been reported.
  • We examined mesothelioma risk in 2567 5-year survivors of Hodgkin lymphoma.
  • Although histology and survival of the mesothelioma cases were comparable with cases from the general population, asbestos exposure and the proportion of males were lower than expected.
  • The evidence for radiotherapy as cause for mesothelioma independent of exposure to asbestos is expanding, and the diagnosis of mesothelioma should be kept in mind whenever related symptoms arise in patients who had previous irradiation.
  • [MeSH-major] Hodgkin Disease / mortality. Hodgkin Disease / radiotherapy. Mesothelioma / mortality. Neoplasms, Radiation-Induced / mortality


66. Toyooka S, Kishimoto T, Date H: Advances in the molecular biology of malignant mesothelioma. Acta Med Okayama; 2008 Feb;62(1):1-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the molecular biology of malignant mesothelioma.
  • Malignant mesothelioma (MM) is a highly aggressive tumor with a dismal prognosis.
  • The incidence of MM is increasing as a result of widespread exposure to asbestos.
  • As in other malignant tumors, genes that are related to immortalization, proliferation, metastasis, angiogenesis, and anti-apoptosis are also overexpressed in MM, contributing to its malignant phenotype.
  • Although the causative role of asbestos is well-known in MM, much less information is available for MM than for other malignant tumors regarding the molecular alterations that occur in the disease.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Mesothelioma / genetics. Neoplasms, Glandular and Epithelial / genetics. Pleural Neoplasms / genetics


67. Nakataki E, Yano S, Matsumori Y, Goto H, Kakiuchi S, Muguruma H, Bando Y, Uehara H, Hamada H, Kito K, Yokoyama A, Sone S: Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor. Cancer Sci; 2006 Mar;97(3):183-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor.
  • Malignant pleural mesothelioma (MPM) is closely related to exposure to asbestos, and a rapid increase in the number of MPM patients in Japan is estimated in the years 2010-2050.
  • EHMES-10 cells overexpressed vascular endothelial growth factor (VEGF), a molecule responsible for malignant effusions, and its receptor.
  • [MeSH-major] Disease Models, Animal. Mesothelioma / metabolism. Pleural Neoplasms / metabolism. Receptors, Vascular Endothelial Growth Factor / biosynthesis. Vascular Endothelial Growth Factor A / biosynthesis


68. Musk AW, de Klerk NH, Reid A, Ambrosini GL, Fritschi L, Olsen NJ, Merler E, Hobbs MS, Berry G: Mortality of former crocidolite (blue asbestos) miners and millers at Wittenoom. Occup Environ Med; 2008 Aug;65(8):541-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality of former crocidolite (blue asbestos) miners and millers at Wittenoom.
  • BACKGROUND: Blue asbestos was mined and milled at Wittenoom in Western Australia between 1943 and 1966.
  • Person-years at risk were derived using two censoring dates in order to produce minimum and maximum estimates of asbestos effect.
  • RESULTS: There have been 190 cases of pleural and 32 cases of peritoneal mesothelioma in this cohort of former workers at Wittenoom.
  • CONCLUSION: Asbestos related diseases, particularly malignant mesothelioma, lung cancer and pneumoconiosis, continue to be the main causes of excess mortality in the former blue asbestos miners and millers of Wittenoom.
  • [MeSH-major] Asbestos, Crocidolite / toxicity. Mesothelioma / mortality. Mining. Occupational Exposure / adverse effects. Peritoneal Neoplasms / mortality. Respiratory Tract Diseases / mortality

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18045848.001).
  • [ISSN] 1470-7926
  • [Journal-full-title] Occupational and environmental medicine
  • [ISO-abbreviation] Occup Environ Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 12001-28-4 / Asbestos, Crocidolite
  •  go-up   go-down


69. Di Serio F, Fontana A, Loizzi M, Capotorto G, Maggiolini P, Mera E, Bisceglia L, Molinini R: Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results. Clin Chem Lab Med; 2007;45(5):634-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results.
  • BACKGROUND: Studies have suggested that soluble mesothelin-related protein (SMRP) can be used as a serum marker of malignant mesothelioma.
  • The serum marker was analysed in 109 healthy subjects never exposed to asbestos, 26 healthy subjects exposed to asbestos, 33 patients with asbestosis, 33 with asbestos-related pleural plaques, 10 with non-malignant pleural diseases, 30 with lung cancer and 24 with histological diagnosis of pleural mesothelioma.
  • RESULTS: Using the International Mesothelioma Interest Group classification, there were nine stage IV, two stage III, four stage II and nine stage I patients.
  • Serum samples from patients with established pleural mesothelioma had significantly higher (p<0.05) concentrations of SMRP than control healthy and patient groups.
  • CONCLUSIONS: SMRP measured on automated systems could be useful for the diagnosis of mesothelioma in routine clinical practice.

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Chem Lab Med. 2008;46(4):565; author reply 566 [18298352.001]
  • (PMID = 17484626.001).
  • [ISSN] 1434-6621
  • [Journal-full-title] Clinical chemistry and laboratory medicine
  • [ISO-abbreviation] Clin. Chem. Lab. Med.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


70. Pesatori AC, Mensi C: Peculiar features of mesothelioma occurrence as related to exposure patterns and circumstances in the Lombard Region, Italy. Med Lav; 2005 Jul-Aug;96(4):354-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peculiar features of mesothelioma occurrence as related to exposure patterns and circumstances in the Lombard Region, Italy.
  • BACKGROUND: The "Lombardy Mesothelioma Registry" started its activity in 2000 in accordance with Italian law DL 277/91.
  • OBJECTIVES AND METHODS: The Registry collects all new incident cases of Malignant Mesothelioma (MM) of pleura, peritoneum, pericardium and vaginal tunic of testis occurring in residents in the Lombardy Region (Northern Italy).
  • For confirmed cases, a standardized questionnaire is administered to the subject or next-of-kin, to verify sources of lifetime asbestos exposure.
  • 21 were peritoneal mesothelioma.
  • Standardized rates for pleural mesothelioma were respectively 3.7 and 1.4 per 100,000 for males and females.
  • Occupational asbestos exposure was ascertained for 71% of male cases and 26% of females.
  • The main relevant exposures were in building trades, metal manufacturing, machine production and maintenance; an unexpectedly high proportion of female cases was engaged in non-asbestos textile factories.
  • CONCLUSIONS: The high proportion of cases with unknown exposure underlines the need to explore new tools and sources to ascertain asbestos exposure.
  • An ad hoc survey in textile industries showed exposure to asbestos to be widely spread in this industry.
  • [MeSH-major] Mesothelioma / diagnosis. Occupational Diseases / diagnosis. Peritoneal Neoplasms / diagnosis. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Asbestos / adverse effects. Carcinogens / toxicity. Female. Humans. Incidence. Italy / epidemiology. Male. Middle Aged. Occupational Exposure / adverse effects. Registries. Retrospective Studies. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16457432.001).
  • [ISSN] 0025-7818
  • [Journal-full-title] La Medicina del lavoro
  • [ISO-abbreviation] Med Lav
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Carcinogens; 1332-21-4 / Asbestos
  •  go-up   go-down


71. Nishimura Y, Miura Y, Maeda M, Hayashi H, Dong M, Katsuyama H, Tomita M, Hyodoh F, Kusaka M, Uesaka A, Kuribayashi K, Fukuoka K, Nakano T, Kashimoto T, Osuki T: Expression of the T cell receptor Vbeta repertoire in a human T cell resistant to asbestos-induced apoptosis and peripheral blood T cells from patients with silica and asbestos-related diseases. Int J Immunopathol Pharmacol; 2006 Oct-Dec;19(4):795-805
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the T cell receptor Vbeta repertoire in a human T cell resistant to asbestos-induced apoptosis and peripheral blood T cells from patients with silica and asbestos-related diseases.
  • To explore the effects of asbestos and silica on the human immune system, an experimental model of low-dose and long-term exposure was established using a human HTLV-1-immortalized polyclonal T cell line, MT-2 (MT-2Org).
  • MT-2 cells were continuously exposed to asbestos at a concentration (10 microg/ml) which does not induce complete cell death during short-term exposure.
  • Patients with asbestos-related diseases (ARD), such as asbestosis and malignant mesothelioma, were compared with silicosis (SIL) patients as a disease control and with healthy donors (HD).
  • SIL and ARD not only differed in their causative materials, silica and asbestos as mineral silicates, but also in terms of complications; autoimmune disorders in SIL and tumors in ARD.
  • These experimental and clinical analyses indicate the superantigenic and dysregulation of autoimmunity-inducing effects of asbestos and silica, respectively.
  • [MeSH-major] Apoptosis / drug effects. Asbestos / toxicity. Asbestosis / immunology. Receptors, Antigen, T-Cell, alpha-beta / genetics. Silicon Dioxide / toxicity. Silicosis / immunology

  • MedlinePlus Health Information. consumer health - Asbestos.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17166401.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, alpha-beta; 1332-21-4 / Asbestos; 7631-86-9 / Silicon Dioxide
  •  go-up   go-down


72. Beyer HL, Geschwindt RD, Glover CL, Tran L, Hellstrom I, Hellstrom KE, Miller MC, Verch T, Allard WJ, Pass HI, Sardesai NY: MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem; 2007 Apr;53(4):666-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MESOMARK: a potential test for malignant pleural mesothelioma.
  • BACKGROUND: Soluble mesothelin-related peptides (SMRP)have been reported to be potential biomarkers for malignant pleural mesothelioma (MPM).
  • SMRP was increased in 52% and 5% of MPM patients and asbestos-exposed individuals, respectively.
  • Concentrations in other nonmalignant and malignant conditions were similar to those in healthy controls.
  • CONCLUSIONS: The MESOMARK assay is analytically robust and may be useful for the detection and management of mesothelioma.
  • [MeSH-major] Biomarkers, Tumor / blood. Membrane Glycoproteins / blood. Mesothelioma / diagnosis. Peptides / blood. Pleural Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17289801.001).
  • [ISSN] 0009-9147
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Peptides; 0 / mesothelin
  •  go-up   go-down


73. Mirabelli D, Cavone D, Merler E, Gennaro V, Romanelli A, Mensi C, Chellini E, Nicita C, Marinaccio A, Magnani C, Musti M: Non-occupational exposure to asbestos and malignant mesothelioma in the Italian National Registry of Mesotheliomas. Occup Environ Med; 2010 Nov;67(11):792-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-occupational exposure to asbestos and malignant mesothelioma in the Italian National Registry of Mesotheliomas.
  • BACKGROUND: Malignant mesotheliomas are strictly related to asbestos, but in a proportion of cases no exposure can be recalled.
  • METHODS: To assess the role of non-occupational exposures in causing malignant mesotheliomas in Italy, the exposures of cases registered by the national mesothelioma registry (ReNaM) were examined.
  • RESULTS: From 1993 to 2001 ReNaM registered 5173 malignant mesothelioma cases, and exposures were assessed in 3552 of them.
  • 144 and 150 cases with exposures limited to environmental (living in the neighbourhood of an industrial or natural source of asbestos) or familial (living with a person occupationally exposed to asbestos) circumstances, respectively, were identified, accounting for 8.3% of all cases.
  • CONCLUSIONS: Geographical variations in the proportion of cases due to non-occupational exposures may be explained by the past distribution of asbestos-using industries.
  • [MeSH-major] Asbestos / toxicity. Environmental Exposure / adverse effects. Mesothelioma / etiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20959396.001).
  • [ISSN] 1470-7926
  • [Journal-full-title] Occupational and environmental medicine
  • [ISO-abbreviation] Occup Environ Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


74. Tomasetti M, Amati M, Santarelli L, Alleva R, Neuzil J: Malignant mesothelioma: biology, diagnosis and therapeutic approaches. Curr Mol Pharmacol; 2009 Jun;2(2):190-206
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma: biology, diagnosis and therapeutic approaches.
  • Malignant mesothelioma (MM) is an aggressive neoplasm of serosal cavities, which is resistant to conventional therapy, with patient survival from presentation of <12 months.
  • Although the main risk factor is asbestos exposure, other factors, Simian virus 40 infection and inheritance of susceptibility genes, likely play a role.
  • Asbestos-related carcinogenic process is primarily based on the interaction between susceptibility (genetic and acquired) and exposure to carcinogenic environmental agents.
  • Asbestos-induced carcinogenesis includes generation of reactive oxygen species, which induce DNA strand breaks and oxidant-induced base modifications to DNA.
  • Several programs have been used to screen asbestos-exposed individuals for lung and pleural disease.
  • [MeSH-major] Mesothelioma / diagnosis
  • [MeSH-minor] Asbestos / toxicity. Carcinogens / toxicity. DNA Damage. Humans. Mitogen-Activated Protein Kinases / metabolism. NF-kappa B / metabolism. Simian virus 40 / physiology. Transcription Factor AP-1 / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021458.001).
  • [ISSN] 1874-4702
  • [Journal-full-title] Current molecular pharmacology
  • [ISO-abbreviation] Curr Mol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Carcinogens; 0 / NF-kappa B; 0 / Transcription Factor AP-1; 1332-21-4 / Asbestos; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  • [Number-of-references] 180
  •  go-up   go-down


75. Kurimoto R, Kishimoto T, Nagai Y, Takazawa H, Sakaue N, Shinohara Y, Hiroshima K: Malignant peritoneal mesothelioma: quantitative analysis of asbestos burden. Pathol Int; 2009 Nov;59(11):823-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peritoneal mesothelioma: quantitative analysis of asbestos burden.
  • Malignant mesotheliomas develop commonly in the pleural cavity and rarely arise in the peritoneal cavity.
  • It is well established that asbestos exposure is related to malignant pleural mesothelioma, but the asbestos burden in the abdominal cavity in patients with malignant peritoneal mesothelioma has not been well studied.
  • The purpose of the present study was therefore to report on an autopsy case of malignant peritoneal mesothelioma with quantitative analysis of the asbestos burden in tissues from the pleura and organs in the abdominal cavity.
  • The patient was a 67-year-old man with a history of asbestos exposure.
  • This patient was diagnosed as having malignant peritoneal epithelioid mesothelioma.
  • The number of asbestos fibers was >10,000/g dry tissue in all samples examined except in the small intestine.
  • The number of asbestos fibers in the stomach was 53,000/g, which was higher than that in a control asbestosis subject.
  • The existence of numerous asbestos fibers found in the abdominal cavity suggests that asbestos stimuli are related to the tumorigenesis of malignant peritoneal mesothelioma.
  • [MeSH-major] Asbestos / adverse effects. Asbestos / analysis. Asbestosis / pathology. Mesothelioma / etiology. Peritoneal Neoplasms / etiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19883435.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Mineral Fibers; 1332-21-4 / Asbestos
  •  go-up   go-down


76. Hasegawa S: [Therapeutic strategies for resectable malignant pleural mesothelioma]. Nihon Geka Gakkai Zasshi; 2009 Nov;110(6):338-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic strategies for resectable malignant pleural mesothelioma].
  • Malignant pleural mesothelioma (MPM) is a rare thoracic malignancy associated with very poor prognosis.
  • The Mesothelioma and Radical Surgery (MARS) trial is a randomized clinical trial seeking to clarify the role of radical surgery in MPM treatment.
  • An all-Japan clinical study of trimodality treatment for MPM is currently underway as a part of a national campaign entitled "Comprehensive Strategy against Asbestos-Related Diseases. "
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999568.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


77. Catalano A, Lazzarini R, Di Nuzzo S, Orciari S, Procopio A: The plexin-A1 receptor activates vascular endothelial growth factor-receptor 2 and nuclear factor-kappaB to mediate survival and anchorage-independent growth of malignant mesothelioma cells. Cancer Res; 2009 Feb 15;69(4):1485-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The plexin-A1 receptor activates vascular endothelial growth factor-receptor 2 and nuclear factor-kappaB to mediate survival and anchorage-independent growth of malignant mesothelioma cells.
  • Here, we show that in asbestos-related malignant pleural mesothelioma (MPM), Semaphorin-6D (Sema6D) and its receptor plexin-A1 are frequently expressed and trigger a prosurvival program that promotes anchorage-independent growth of MPM cells.
  • Expression of Sema6D and plexin-A1 is induced by asbestos fibers and overexpression of plexin-A1 in nonmalignant mesothelial cells inhibits cell death after asbestos exposure.
  • [MeSH-major] Mesothelioma / pathology. NF-kappa B / genetics. Nerve Tissue Proteins / genetics. Pleural Neoplasms / pathology. Receptors, Cell Surface / genetics. Vascular Endothelial Growth Factor Receptor-2 / genetics

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19176370.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Nerve Tissue Proteins; 0 / PLXNA1 protein, human; 0 / RNA, Neoplasm; 0 / Receptors, Cell Surface; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


78. Rezaei Kalantari H: [Malignant peritoneal mesothelioma: a case report]. Rev Med Liege; 2010 Sep;65(9):490-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant peritoneal mesothelioma: a case report].
  • I report two cases of malignant peritoneal mesothelioma.
  • Mesothelioma is mostly a pleural disease whether visceral or parietal.
  • Infra-diaphragmatic Mesothelioma accounts for only 10-20% of all mesotheliomas.
  • In over 80% of the cases the pathogenesis is related to asbestos and radiation exposure.
  • One of our two patients has non past history of exposure to asbestos.
  • Prognosis for patients with malignant peritoneal mesothelioma is very poor with a mean survival of 5,4 months versus 12.5 months for pleural mesothelioma.
  • Peritoneal mesothelioma, although rare, should be considered among the differential diagnosis of ascites differential diagnosis work up.
  • [MeSH-major] Mesothelioma / diagnosis. Peritoneal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21086578.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


79. Szeszenia-Dabrowska N: [Asbestos as a risk factor for pulmonary diseases]. Przegl Lek; 2008;65 Suppl 2:26-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Asbestos as a risk factor for pulmonary diseases].
  • Asbestos is a recognised carcinogen, one of the most dangerous pollutants in the human environment.
  • This is associated with a huge accumulation of asbestos-containing materials that, as a result of their degradation, release fibres that are practically indestructible.
  • It is estimated that in recent years, asbestos was responsible for ca.
  • The pathogenic effects of asbestos on the respiratory system (the target organ) result from the inhalation of the respirable asbestos fibres suspended in the ambient air.
  • A specific feature of asbestos activity is that the pathologies appear even after cessation of the exposure; another feature is the development of mesotheliomas associated with the environmental exposure.
  • In Poland, the Act of 1997 banning the use of asbestos products has solved the problems associated with the occupational exposure in the asbestos processing industry, and prevented further accumulation of asbestos products.
  • However, problems of the environmental exposures to asbestos remain unsolved.
  • In spite that no worker has been occupationally exposed to asbestos during the recent 10 years, new cases of asbestosis, lung cancer pleural mesothelioma, non-malignant pleural diseases continue to be detected each year among the former workers of asbestos processing industry ("Amiantus" project).
  • This paper reports on the current status of asbestos-related diseases in Poland and worldwide, risk of the development of lung cancers and asbestos-specific mesotheliomas and gives recent recommendations for diagnosing and certification of asbestos-related diseases.
  • [MeSH-major] Asbestos / adverse effects. Occupational Exposure / prevention & control. Respiratory Tract Diseases / epidemiology

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19621651.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  • [Number-of-references] 17
  •  go-up   go-down


80. Sherwood AL, Mutsaers SE, Peeva VK, Robinson C, DeSilva CJ, Swanson NR, Lake RA: Spontaneously immortalized mouse mesothelial cells display characteristics of malignant transformation. Cell Prolif; 2008 Dec;41(6):894-908
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneously immortalized mouse mesothelial cells display characteristics of malignant transformation.
  • OBJECTIVES: Mesotheliomas occur in occult serous cavities after chronic exposure of mesothelial cells to asbestos fibres.
  • Comparative gene expression analysis demonstrated that spontaneously transformed cell lines were more closely related to neoplastic cells than to primary cells.
  • [MeSH-minor] Animals. Cell Aging / drug effects. Cell Line, Transformed. Cell Shape / drug effects. DNA / analysis. Down-Regulation / drug effects. Gene Deletion. Gene Expression Profiling. Genes, Tumor Suppressor. Humans. Intercellular Signaling Peptides and Proteins / pharmacology. Mesothelioma / genetics. Mice. Mice, Inbred C57BL

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19040568.001).
  • [ISSN] 1365-2184
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 9007-49-2 / DNA
  •  go-up   go-down


81. Tsou MT, Luo JC: Porcelain factory worker with asbestos-related mesothelioma. J Formos Med Assoc; 2009 Oct;108(10):819-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Porcelain factory worker with asbestos-related mesothelioma.
  • Malignant mesothelioma is a rare tumor among the general population, but for people exposed to asbestos, the lifetime risk is high.
  • A chest X-ray revealed right-side pleural effusion; however, pleural biopsy from drainage treatment confirmed a diagnosis of malignant mesothelioma.
  • The specific characteristics of his work, making asbestos wallboards and gaskets, entailed working in high-temperature conditions with a high fine-particle content in the atmosphere.
  • The high working temperature caused asbestos debris and dust to fall down regularly from the wallboards, however, it was not until recently that the patient had started to wear personal protection.
  • Asbestos is a significant source of hazardous exposure in old buildings, and this case serves as a reminder of the importance of asbestos-related exposure history, which facilitated the correct diagnosis of pulmonary malignant mesothelioma.
  • Asbestos-containing materials that are now banned or regulated are still present in older buildings and remain an exposure hazard; they continue to be a serious health concern in many countries.

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Formos Med Assoc. 2010 May;109(5):389 [20497872.001]
  • (PMID = 19864204.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


82. Creaney J, Musk AW, Robinson BW: Sensitivity of urinary mesothelin in patients with malignant mesothelioma. J Thorac Oncol; 2010 Sep;5(9):1461-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity of urinary mesothelin in patients with malignant mesothelioma.
  • INTRODUCTION: Malignant mesothelioma (MM) is an aggressive, uniformly fatal tumor usually caused by exposure to asbestos.
  • As urine is less complex and less invasive to collect than serum and may be a more acceptable specimen for large-scale screening studies of asbestos-exposed individuals, we determined whether the sensitivity and specificity for MM could be improved by measuring soluble mesothelin in the urine.
  • METHODS: Soluble mesothelin concentrations were determined using the MESOMARK assay in concurrent serum and urine samples from 70 patients with pleural MM, 111 patients with asbestos-related lung or pleural disease, and 45 patients with benign nonasbestos-related lung and pleural disease.
  • [MeSH-major] Asbestos / adverse effects. Biomarkers, Tumor / urine. Membrane Glycoproteins / urine. Mesothelioma / urine. Pleural Neoplasms / urine

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20815094.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 1332-21-4 / Asbestos; AYI8EX34EU / Creatinine
  •  go-up   go-down


83. Watanabe Y, Kojima T, Kagawa S, Uno F, Hashimoto Y, Kyo S, Mizuguchi H, Tanaka N, Kawamura H, Ichimaru D, Urata Y, Fujiwara T: A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy. Oncogene; 2010 Feb 25;29(8):1145-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy.
  • Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that is related to asbestos exposure.
  • In this study, we show that telomerase-specific, replication-selective adenovirus OBP-301 can efficiently infect and kill human mesothelioma cells by viral replication.
  • Intrathoracic administration of virus significantly reduced the number and size of human mesothelioma tumors intrathoracically implanted into nu/nu mice.
  • A high-definition, fluorescence optical imaging system with an ultra-thin, flexible fibered microprobe clearly detected intracellular replication of green fluorescent protein-expressing oncolytic virus in intrathoracically established mesothelioma tumors.
  • Our results suggest that intrathoracic dual virotherapy with telomerase-specific oncolytic adenovirus in combination with heparanase-expressing adenovirus may be efficacious in the prevention and treatment of pleural dissemination of human malignant mesothelioma.
  • [MeSH-major] Adenoviridae / genetics. Genetic Therapy. Glucuronidase / genetics. Mesothelioma / therapy. Oncolytic Virotherapy. Pleural Neoplasms / therapy. Transfection / methods


84. Wang Y, Rishi AK, Puliyappadamba VT, Sharma S, Yang H, Tarca A, Dou QP, Lonardo F, Ruckdeschel JC, Pass HI, Wali A: Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines. Cancer Chemother Pharmacol; 2010 Aug;66(3):455-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.
  • Malignant pleural mesothelioma (MPM) is an asbestos-related tumor of the thoracic pleura that lacks effective treatment options.
  • Pretreatment of mesothelioma cells with Velcade showed synergistic effect with cisplatin combination regimens.
  • High-throughput gene expression profiling among Velcade treated and untreated mesothelioma cell lines resulted in identification of novel transducers of apoptosis such as CARP-1, XAF1, and Troy proteins.
  • This pilot study has paved way for further in-depth analysis of the downstream target molecules associated with presensitization of mesothelioma cells in finding effective therapeutic treatment options for both mesothelioma and recalcitrant breast cancers.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Apoptosis / drug effects. Breast Neoplasms / drug therapy. Mesothelioma / drug therapy. Protease Inhibitors / pharmacology


85. Amati M, Tomasetti M, Scartozzi M, Mariotti L, Alleva R, Pignotti E, Borghi B, Valentino M, Governa M, Neuzil J, Santarelli L: Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study. Cancer Epidemiol Biomarkers Prev; 2008 Jan;17(1):163-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study.
  • Improved detection methods for diagnosis of asymptomatic malignant mesothelioma (MM) are essential for an early and reliable detection and treatment of this type of neoplastic disease.
  • Ninety-four asbestos-exposed subjects defined at high risk, 22 patients with MM, and 54 healthy subjects were recruited for evaluation of the clinical significance of 8-hydroxy-2'-deoxyguanosine (8OHdG) in WBCs and plasma concentrations of soluble mesothelin-related peptides (SMRPs), angiogenic factors [platelet-derived growth factor beta, hepatocyte growth factor, basic fibroblast growth factor, and vascular endothelial growth factor beta (VEGFbeta)], and matrix proteases [matrix metalloproteinase (MMP) 2, MMP9, tissue inhibitor of metalloproteinase (TIMP) 1, and TIMP2] for potential early detection of MM.
  • The area under receiver operating characteristic (ROC) curves indicate that 8OHdG levels can discriminate asbestos-exposed subjects from healthy controls but not from MM patients.
  • Significant area under ROC curve values were found for SMRPs, discriminating asbestos-exposed subjects from MM patients but not from healthy controls.
  • The combination of blood biomarkers and radiographic findings could be used to stratify the risk of mesothelioma in asbestos-exposed populations.
  • [MeSH-major] Asbestosis / blood. Biomarkers, Tumor / blood. Mesothelioma / blood

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18199721.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Biomarkers, Tumor; 0 / Tissue Inhibitor of Metalloproteinase-1; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


86. Scattone A, Pennella A, Gentile M, Musti M, Nazzaro P, Buonadonna AL, Marzullo A, Cavone D, Pollice L, Serio G: Comparative genomic hybridisation in malignant deciduoid mesothelioma. J Clin Pathol; 2006 Jul;59(7):764-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative genomic hybridisation in malignant deciduoid mesothelioma.
  • BACKGROUND: Malignant deciduoid mesothelioma is a rare variant of epithelioid mesothelioma.
  • This tumour generally has poor prognosis, and can be asbestos related.
  • AIM: To identify peculiar genetic changes responsible for critical phases in pathogenesis of malignant deciduoid mesothelioma and their prognostic relevance.
  • METHODS: Comparative genomic hybridisation was carried out in six cases of malignant pleural deciduoid mesothelioma, four sporadic and two familial.
  • All cases were found to be asbestos related.
  • The clinical outcome for this mesothelioma subtype is predicted by the number of losses.
  • [MeSH-major] Chromosome Aberrations. Mesothelioma / genetics. Pleural Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Asbestos / adverse effects. Female. Humans. Image Processing, Computer-Assisted. Immunoenzyme Techniques. Male. Middle Aged. Nucleic Acid Hybridization / methods. Occupational Diseases / etiology. Occupational Diseases / genetics. Occupational Diseases / pathology. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Aug;24(8):1179 [10935666.001]
  • [Cites] Virchows Arch. 1999 Mar;434(3):263-6 [10190309.001]
  • [Cites] Thorax. 2000 Sep;55(9):731-5 [10950889.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1440-3 [11023112.001]
  • [Cites] Clin Ter. 2000 Nov-Dec;151(6):433-8 [11211478.001]
  • [Cites] J Mol Diagn. 2000 Nov;2(4):209-16 [11232111.001]
  • [Cites] Cytopathology. 2001 Feb;12(1):57-61 [11256939.001]
  • [Cites] Am J Surg Pathol. 2001 Apr;25(4):547-8 [11257636.001]
  • [Cites] Cancer Genet Cytogenet. 2001 May;127(1):80-2 [11408072.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Aug;31(4):333-44 [11433524.001]
  • [Cites] Ann Diagn Pathol. 2001 Jun;5(3):168-71 [11436171.001]
  • [Cites] Histopathology. 2001 Jul;39(1):104-6 [11454052.001]
  • [Cites] Oncogene. 2001 Sep 27;20(43):6245-9 [11593434.001]
  • [Cites] Diagn Cytopathol. 2002 Feb;26(2):117-22 [11813331.001]
  • [Cites] Indian J Pathol Microbiol. 2001 Apr;44(2):159-62 [11883137.001]
  • [Cites] Histopathology. 2002 Apr;40(4):348-52 [11943019.001]
  • [Cites] J Pathol. 2002 Jul;197(3):363-71 [12115883.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Oct 1;138(1):73-6 [12419589.001]
  • [Cites] Cancer Biol Ther. 2002 Jul-Aug;1(4):348-53 [12432244.001]
  • [Cites] Ultrastruct Pathol. 2002 Nov-Dec;26(6):355-63 [12537760.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3B):2281-9 [12894504.001]
  • [Cites] Pathol Int. 2004 Jan;54(1):67-72 [14674999.001]
  • [Cites] Pathol Int. 2004 Aug;54(8):549-55 [15260845.001]
  • [Cites] Am J Clin Pathol. 1981 Jun;75(6):816-21 [6167159.001]
  • [Cites] Am J Surg Pathol. 1985 Jan;9(1):73-80 [3970301.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Mar;59(1):57-61 [1555192.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4349-55 [8364929.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2156-60 [8134364.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1801-6 [8137295.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):439-45 [7513500.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Aug;10(4):231-43 [7522536.001]
  • [Cites] Am J Pathol. 1994 Dec;145(6):1301-8 [7992835.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):342-7 [7529134.001]
  • [Cites] J Cell Physiol. 1999 Aug;180(2):150-7 [10395284.001]
  • [Cites] Chest. 1999 Aug;116(2):504-20 [10453882.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):683-94 [10487825.001]
  • [Cites] Histopathology. 2004 Dec;45(6):643-5 [15569059.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Nov;11(3):153-62 [7530484.001]
  • [Cites] Chest. 1995 Oct;108(4):1122-8 [7555126.001]
  • [Cites] Am J Hum Genet. 1995 Nov;57(5):1211-20 [7485173.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Jul 1;89(1):7-13 [8689616.001]
  • [Cites] Br J Cancer. 1997;75(4):523-7 [9052404.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):4057-62 [9307293.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):285-94 [10680897.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):816-23 [10843283.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Jul;28(3):337-41 [10862040.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Aug;28(4):395-403 [10862048.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jan 1;100(1):25-30 [9406576.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):145-52 [9440736.001]
  • [Cites] Br J Cancer. 1998;77(2):260-9 [9460997.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):450-4 [9927061.001]
  • [Cites] Respiration. 2000;67(4):456-8 [10940805.001]
  • (PMID = 16569690.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  • [Other-IDs] NLM/ PMC1860431
  •  go-up   go-down


87. Guled M, Lahti L, Lindholm PM, Salmenkivi K, Bagwan I, Nicholson AG, Knuutila S: CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis. Genes Chromosomes Cancer; 2009 Jul;48(7):615-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis.
  • Malignant mesothelioma (MM) is an aggressive cancer arising from mesothelial cells, mainly due to former asbestos exposure.
  • Regarding risk factors such as smoking status and asbestos exposure, significantly differentially expressed miRNAs were identified in smokers versus nonsmokers (miR-379, miR-301a, miR-299-3p, miR-455-3p, and miR-127-3p), but not in asbestos-exposed patients versus nonexposed ones.
  • This could be related to the method of assessment of asbestos exposure as asbestos remains to be the main contributor to the development of MM.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / genetics. Gene Expression Regulation, Neoplastic. Mesothelioma / genetics. MicroRNAs / genetics. Neurofibromin 2 / genetics. Proto-Oncogene Proteins c-jun / genetics
  • [MeSH-minor] Aged. Asbestos / poisoning. Chromosomes, Human. Cluster Analysis. Female. Gene Expression Profiling / methods. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis / methods. Risk Factors. Smoking / genetics. Smoking / metabolism. Survival Analysis


88. Kurata S, Ishibashi M, Azuma K, Kaida H, Takamori S, Fujimoto K, Kobayashi M, Hirose Y, Aizawa H, Hayabuchi N: Preliminary study of positron emission tomography/computed tomography and plasma osteopontin levels in patients with asbestos-related pleural disease. Jpn J Radiol; 2010 Jul;28(6):446-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary study of positron emission tomography/computed tomography and plasma osteopontin levels in patients with asbestos-related pleural disease.
  • PURPOSE: The aim of this study was to compare the results of semiquantitative analysis by(18)F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) with plasma osteopontin levels in the same asbestos-related pleural disease population.
  • MATERIALS AND METHODS: A total of 17 patients with asbestos-related pleural disease were prospectively recruited.
  • RESULTS: Malignant pleural mesothelioma (MPM) was histologically proven in 6 patients, and 11 patients had proven benign asbestos-related pleural diseases (7 pleural plaques, 4 asbestos pleurisy).
  • Significant differences in SUVmax were found between patients with MPM and those with asbestos pleurisy (P = 0.031) and between patients with MPM and those with pleural plaques (P = 0.012).
  • A significant difference was found in the plasma osteopontin levels between patients with asbestos pleurisy and patients with pleural plaques (Bonferroni correction, P = 0.024).
  • The SUVmax in patients with benign asbestos-related diseases was statistically positively correlated with plasma osteopontin in the same group (Spearman's r = 0.75, P < 0.05).
  • CONCLUSION: PET/CT might be more helpful than plasma osteopontin for distinguishing benign asbestos-related pleural diseases from MPM, and the SUVmax in benign asbestos-related pleural diseases may reflect changes in pleural inflammation.
  • [MeSH-major] Asbestos / toxicity. Mesothelioma / diagnostic imaging. Osteopontin / blood. Pleural Diseases / diagnostic imaging. Positron-Emission Tomography / methods. Tomography, Spiral Computed / methods

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 2004 Feb;125(2):489-93 [14769729.001]
  • [Cites] AJR Am J Roentgenol. 1999 Apr;172(4):1039-47 [10587144.001]
  • [Cites] Tumori. 2002 Jul-Aug;88(4):266-9 [12400973.001]
  • [Cites] Lung Cancer. 2008 Mar;59(3):411-20 [18061303.001]
  • [Cites] Cytokine Growth Factor Rev. 2003 Dec;14(6):479-88 [14563350.001]
  • [Cites] J Nucl Med. 2001 Oct;42(10):1551-5 [11585872.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1362-6 [19174489.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1671-9 [11926891.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Jun;129(6):1364-70 [15942579.001]
  • [Cites] J Nucl Med. 2007 Jan;48(1):35-45 [17204697.001]
  • [Cites] J Nucl Med. 2002 Sep;43(9):1144-9 [12215551.001]
  • [Cites] Eur J Radiol. 2007 Dec;64(3):356-66 [17954021.001]
  • [Cites] Eur J Cardiothorac Surg. 2000 Apr;17 (4):377-83 [10773558.001]
  • [Cites] Ann Thorac Surg. 1999 Nov;68(5):1799-804 [10585061.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1564-73 [16221779.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Jul;126(1):11-6 [12878934.001]
  • [Cites] Thorac Cardiovasc Surg. 2009 Jun;57(4):217-21 [19670115.001]
  • [Cites] Exp Oncol. 2004 Sep;26(3):179-84 [15494684.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S27-32 [15950796.001]
  • [Cites] J Nucl Med. 2004 Jun;45(6):995-8 [15181135.001]
  • [Cites] Curr Opin Pulm Med. 2007 Jul;13(4):339-443 [17534183.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2928-35 [17504993.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1591-603 [16221782.001]
  • [Cites] Clin Imaging. 2006 May-Jun;30(3):177-80 [16632152.001]
  • [Cites] Radiol Clin North Am. 1992 Nov;30(6):1177-89 [1410307.001]
  • [Cites] Chest. 1998 Sep;114(3):713-22 [9743156.001]
  • (PMID = 20661695.001).
  • [ISSN] 1867-108X
  • [Journal-full-title] Japanese journal of radiology
  • [ISO-abbreviation] Jpn J Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 106441-73-0 / Osteopontin; 1332-21-4 / Asbestos
  •  go-up   go-down


89. Munkholm-Larsen S, Cao CQ, Yan TD: Malignant peritoneal mesothelioma. World J Gastrointest Surg; 2009 Nov 30;1(1):38-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peritoneal mesothelioma.
  • Malignant mesothelioma is a highly aggressive neoplasm.
  • The incidence of malignant mesothelioma is increasing worldwide.
  • Diffuse malignant peritoneal mesothelioma (DMPM) represents one-fourth of all mesotheliomas.
  • Association of asbestos exposure with DMPM has been observed, especially in males.
  • This remarkable improvement in survival has prompted new search into the medical science related to DMPM, a disease previously ignored as uninteresting.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160794.001).
  • [ISSN] 1948-9366
  • [Journal-full-title] World journal of gastrointestinal surgery
  • [ISO-abbreviation] World J Gastrointest Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999110
  • [Keywords] NOTNLM ; Asbestos / Cisplatin / Cytoreductive surgery / Doxorubicin / Intraperitoneal chemotherapy / Mesothelin / Pemetrexed / Peritoneal mesothelioma / Peritonectomy
  •  go-up   go-down


91. Montomoli L, Spisso M, Romeo R, Spina D, Ghiribelli C, Sartorelli P: [Work related mesothelioma: analysis of cases discovered at the Section for Occupational Medicine and Toxicology of Siena University during the years 2000-2007]. G Ital Med Lav Ergon; 2007 Jul-Sep;29(3 Suppl):332-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Work related mesothelioma: analysis of cases discovered at the Section for Occupational Medicine and Toxicology of Siena University during the years 2000-2007].
  • This study focuses on the spread of mesothelioma in Siena.
  • The association between malignant masothelioma and exposure to asbestos was deduced by the occupational history.
  • The mesothelioma was noted both in traditional industries and other jobs such as the chain of manifacture, plumbers, electricians, carpenters, installers of asbestos insulation and construction workers.
  • Thus it is possible to find other malignant and nonmalignant asbestos-related diseases more frequently than mesothelioma.
  • [MeSH-major] Mesothelioma / epidemiology. Occupational Diseases / epidemiology. Pleural Neoplasms / epidemiology
  • [MeSH-minor] Aged. Asbestos / adverse effects. Female. Humans. Italy. Male. Universities

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18409711.001).
  • [ISSN] 1592-7830
  • [Journal-full-title] Giornale italiano di medicina del lavoro ed ergonomia
  • [ISO-abbreviation] G Ital Med Lav Ergon
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


92. Otsuki T, Maeda M, Murakami S, Hayashi H, Miura Y, Kusaka M, Nakano T, Fukuoka K, Kishimoto T, Hyodoh F, Ueki A, Nishimura Y: Immunological effects of silica and asbestos. Cell Mol Immunol; 2007 Aug;4(4):261-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunological effects of silica and asbestos.
  • Silicosis patients (SILs) and patients who have been exposed to asbestos develop not only respiratory diseases but also certain immunological disorders.
  • In addition, malignant complications such as lung cancer and malignant mesothelioma often occur in patients exposed to asbestos, and may be involved in the reduction of tumor immunity.
  • A brief summary of our investigations related to the immunological effects of silica/asbestos is presented.
  • Recent advances in immunomolecular studies led to detailed analyses of the immunological effects of asbestos and silica.
  • Both affect immuno-competent cells and these effects may be associated with the pathophysiological development of complications in silicosis and asbestos-exposed patients such as the occurrence of autoimmune disorders and malignant tumors, respectively.
  • In particular, as the incidence of asbestos-related malignancies is increasing and such malignancies have been a medical and social problem since the summer of 2005 in Japan, efforts should be focused on developing a cure for these diseases to eliminate nationwide anxiety.
  • [MeSH-major] Asbestos / immunology. Silicon Dioxide / immunology

  • MedlinePlus Health Information. consumer health - Asbestos.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17764616.001).
  • [ISSN] 1672-7681
  • [Journal-full-title] Cellular & molecular immunology
  • [ISO-abbreviation] Cell. Mol. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Autoantibodies; 1332-21-4 / Asbestos; 7631-86-9 / Silicon Dioxide
  • [Number-of-references] 72
  •  go-up   go-down


93. Betti M, Neri M, Ferrante D, Landi S, Biava A, Gemignani F, Bertolotti M, Mirabelli D, Padoan M, Ugolini D, Botta M, Bonassi S, Magnani C, Dianzani I: Pooled analysis of NAT2 genotypes as risk factors for asbestos-related malignant mesothelioma. Int J Hyg Environ Health; 2009 May;212(3):322-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pooled analysis of NAT2 genotypes as risk factors for asbestos-related malignant mesothelioma.
  • Malignant mesothelioma (MM) is a rare and aggressive tumor of the pleura.
  • The most important causal factor for the development of MM is occupational exposure to asbestos.
  • To ascertain the role of NAT2 genotype, we performed a study on 252 MM patients and 262 controls recruited in two Northern Italy areas that were characterized by high asbestos exposure, due to intense industrial activities (an asbestos cement factory in Casale Monferrato, mainly shipyards and refineries in Liguria).
  • NAT2 fast acetylator genotypes showed an increased OR, although not statistically significant, both in asbestos-exposed subjects (OR=1.47; 95% CI=0.96-2.26) and in the entire population (OR=1.38; 95% CI=0.93-2.04).
  • [MeSH-major] Arylamine N-Acetyltransferase / genetics. Asbestos / adverse effects. Carcinogens. Genetic Predisposition to Disease. Mesothelioma / genetics. Pleural Neoplasms / genetics. Polymorphism, Genetic

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18838334.001).
  • [ISSN] 1618-131X
  • [Journal-full-title] International journal of hygiene and environmental health
  • [ISO-abbreviation] Int J Hyg Environ Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carcinogens; 1332-21-4 / Asbestos; EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / NAT2 protein, human
  •  go-up   go-down


94. Marinaccio A, Binazzi A, Cauzillo G, Chellini E, De Zotti R, Gennaro V, Menegozzo M, Mensi C, Merler E, Mirabelli D, Musti M, Pannelli F, Romanelli A, Scarselli A, Tosi S, Tumino R, Nesti M, Gruppo di lavoro ReNaM: [Epidemiological surveillance of malignant mesothelioma cases in Italy: incidence and asbestos exposure figures by the Italian mesothelioma registry (ReNaM)]. Epidemiol Prev; 2007 Jul-Aug;31(4 Suppl 1):23-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiological surveillance of malignant mesothelioma cases in Italy: incidence and asbestos exposure figures by the Italian mesothelioma registry (ReNaM)].
  • The Study describes the epidemiological surveillance of mesothelioma cases carried out by the Italian mesothelioma register (ReNaM).
  • A Regional Operating Centre (COR) is present in nearly all Italian regions (17 out of 20) and it collects malignant mesothelioma cases and investigate the modalities of asbestos exposure by using a structured questionnaire.
  • The register produces malignant mesothelioma incidence measures and analyses of the modalities of the asbestos exposure.
  • The standardized incidence rate of malignant mesothelioma in 2001 was 2.98 (in 100,000 inhabitants) among men and 0.98 among women; a professional (certain, probable, possible) exposure has been detected in 67.4% of defined cases.
  • In addition to the conventional sectors (shipbuilding, railways repair and demolition, asbestos-cement production), also textile, building, transport, chemical and glass industries, petroleum and sugar refineries, electricity production and distribution plants are getting involved.
  • Despite the absence of some regions completing the national coverage and the non homogeneity in collecting and coding data, the epidemiological surveillance of malignant mesothelioma carried out by ReNaM is an important tool for the scientific knowledge and the prevention of asbestos-related diseases.
  • [MeSH-major] Asbestos / adverse effects. Mesothelioma / epidemiology. Mesothelioma / etiology. Occupational Diseases / epidemiology. Occupational Diseases / etiology. Occupational Exposure / adverse effects. Pleural Neoplasms / epidemiology. Pleural Neoplasms / etiology


95. Chapman EA, Thomas PS, Yates DH: Breath analysis in asbestos-related disorders: a review of the literature and potential future applications. J Breath Res; 2010 Sep;4(3):034001
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breath analysis in asbestos-related disorders: a review of the literature and potential future applications.
  • Asbestos usage was very common worldwide in the last century and continues in several countries today.
  • Several diseases occur due to asbestos exposure, including malignant tumours such as malignant mesothelioma of the pleura and lung cancer, which have a very poor prognosis.
  • Asbestos inhalation may also result in more benign conditions such as asbestosis (or pulmonary fibrosis due to asbestos), pleural plaques and pleural thickening.
  • It is predicted that asbestos-associated mortality and morbidity will continue to increase, but methods for diagnosing asbestos-related disease are currently invasive and unsuitable for an increasingly elderly population.
  • [MeSH-major] Asbestos / analysis. Asbestosis / diagnosis

  • MedlinePlus Health Information. consumer health - Asbestos.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21383477.001).
  • [ISSN] 1752-7163
  • [Journal-full-title] Journal of breath research
  • [ISO-abbreviation] J Breath Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 1332-21-4 / Asbestos
  •  go-up   go-down


96. Greillier L, Astoul P: Mesothelioma and asbestos-related pleural diseases. Respiration; 2008;76(1):1-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelioma and asbestos-related pleural diseases.
  • At present, the use of asbestos is not regulated at a worldwide scale.
  • Moreover, there is a latency period between asbestos exposure and the manifestations of asbestos-related diseases.
  • Consequently, pulmonologists are still dealing with consequences of asbestos exposure, which mainly occur at the pleural surface.
  • The aim of this review is to provide an overview of asbestos-related pleural diseases.
  • We summarized the most relevant data for the diagnosis and the management of benign asbestos pleural effusions, pleural plaques, diffuse pleural thickening and rounded atelectasis.
  • Special attention is dedicated to malignant pleural mesothelioma, given the challenging issues of this disease, the recent advances in its management and the dynamism of research in this area.
  • [MeSH-major] Asbestosis. Mesothelioma. Pleural Diseases. Pleural Neoplasms

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel.
  • (PMID = 18583923.001).
  • [ISSN] 1423-0356
  • [Journal-full-title] Respiration; international review of thoracic diseases
  • [ISO-abbreviation] Respiration
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 189
  •  go-up   go-down


97. Takemura Y, Satoh M, Satoh K, Hamada H, Sekido Y, Kubota S: High dose of ascorbic acid induces cell death in mesothelioma cells. Biochem Biophys Res Commun; 2010 Apr 2;394(2):249-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose of ascorbic acid induces cell death in mesothelioma cells.
  • Malignant mesothelioma is an asbestos-related fatal disease with no effective cure.
  • We studied whether high dose of ascorbic acid induced cell death of four human mesothelioma cell lines.
  • High dose of ascorbic acid induced cell death of all mesothelioma cell lines in a dose-dependent manner.
  • In vivo experiment, intravenous administration of ascorbic acid significantly decreased the growth rate of mesothelioma tumor inoculated in mice.
  • These data suggest that ascorbic acid may have benefits for patients with mesothelioma.
  • [MeSH-major] Apoptosis. Ascorbic Acid / administration & dosage. Mesothelioma / drug therapy

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Vitamin C.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20171954.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Reactive Oxygen Species; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


98. Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, de Klerk NH, Skates SJ, Robinson BW: Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomarkers Prev; 2010 Sep;19(9):2238-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.
  • BACKGROUND: Malignant mesothelioma is an aggressive, almost uniformly fatal tumor, primarily caused by exposure to asbestos.
  • Since the recent discovery that serum mesothelin is a sensitive and highly specific biomarker for mesothelioma, one of the key issues raised is whether mesothelin levels represent a useful screening test for asbestos-exposed at-risk individuals.
  • In this study, soluble mesothelin was determined in sequential serum samples collected from asbestos-exposed individuals before the development of mesothelioma.
  • METHODS: Archival serum samples from 106 individuals who developed mesothelioma, 99 asbestos-exposed individuals from the Wittenoom Cancer Surveillance Program, and 109 non-asbestos-exposed individuals from the Busselton Health Survey were identified.
  • RESULTS: Longitudinal mesothelin levels determined in healthy asbestos-exposed individuals over a period of 4 years were stable (Pearson's r = 0.96; P < 0.0001).
  • There was no correlation between mesothelin concentration and cumulative asbestos exposure.
  • Mesothelin concentrations were greater than the threshold value of 2.5 nmol/L in the penultimate serum sample before the diagnosis of mesothelioma in 17 of 106 people.
  • CONCLUSION: In a population with a high pretest probability of developing mesothelioma, the serum biomarker mesothelin is elevated in absolute terms in 15% and in relative terms in 40% of the group.
  • [MeSH-major] Asbestos / adverse effects. Biomarkers, Tumor / blood. Membrane Glycoproteins / blood. Mesothelioma / blood. Mesothelioma / etiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2010 AACR.
  • (PMID = 20651076.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 1332-21-4 / Asbestos
  •  go-up   go-down


99. Petazzi A, Gaudiello F, Canti Z, Mensi C: [Cluster cases of malignant pleural mesothelioma in an oil factory]. Med Lav; 2005 Sep-Oct;96(5):440-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cluster cases of malignant pleural mesothelioma in an oil factory].
  • No cases are reported in literature of asbestos related disease in subjects who worked in oil factories.
  • Nevertheless the structure and organization of the workplace, which is similar to that of sugar refineries, where cases of malignant mesothelioma have been described (moreover in workers employed in running and maintenance of the plants), led to the assumption that even in oil factories asbestos for the insulation of pipes and boilers could be present.
  • OBJECTIVES: To describe 3 cases of Malignant Mesothelioma that occurred in workers of the same oil factory.
  • METHODS: Since this occupational sector is not conventionally known for asbestos exposure the Local Health Unit and the Lombardy Mesothelioma Registry decided to investigate this industrial plant.
  • RESULTS: Following examination of the archives of the Local Health Unit and inspection of the plant, an environmental asbestos contamination (pipes and boilers) was found.
  • This underlines the importance of close cooperation with Local Health Units of occupational medicine and the Regional Mesothelioma Registry in the study and acknowledgment of cases which would otherwise not have been recognized, with consequent loss of precious information.
  • [MeSH-major] Air Pollutants, Occupational / adverse effects. Asbestos / adverse effects. Chemical Industry. Mesothelioma / epidemiology. Occupational Diseases / epidemiology. Petroleum. Pleural Neoplasms / epidemiology


100. Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, Canessa PA, Chella A, Lucchi M, Mussi A, Mutti L: Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma. Int J Biol Markers; 2010 Jul-Sep;25(3):164-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma.
  • BACKGROUND: A potential role of serum osteopontin (OPN) and serum mesothelin-related peptide (SMRP) in the diagnosis of malignant pleural mesothelioma (MPM) has been recently reported.
  • Our study aimed to evaluate the influence of preanalytic variables on serum and plasma OPN, to compare serum and plasma OPN in the same population, and to assess whether OPN levels can aid in the diagnostic distinction of patients with MPM versus benign respiratory disease (BRD) and healthy subjects exposed to asbestos.
  • We measured OPN in 239 plasma samples from 207 asbestos-exposed subjects including 94 healthy controls and 113 subjects with BRD, and 32 patients with epithelial MPM, employing a commercially available ELISA.
  • Within the control group no significant correlation was observed between age, duration of asbestos exposure, pack-years in current smokers, lung function or imaging parameters and plasma or serum OPN.
  • CONCLUSIONS: These data suggest that plasma OPN and serum OPN are not influenced by confounding factors such as age, smoking habits and asbestos exposure.
  • [MeSH-major] Asbestos / adverse effects. Biomarkers, Tumor / blood. Mesothelioma / blood. Osteopontin / blood. Pleural Neoplasms / blood. Specimen Handling

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Biospecimen Research Database. Biospecimen Research Database .
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20878622.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 106441-73-0 / Osteopontin; 1332-21-4 / Asbestos
  •  go-up   go-down






Advertisement